

B2

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12Q 1/68, C07K 16/18, A61K 38/17	A2	(11) International Publication Number: WO 00/17355 (43) International Publication Date: 30 March 2000 (30.03.00)
(21) International Application Number: PCT/US99/21565 (22) International Filing Date: 17 September 1999 (17.09.99) (30) Priority Data: 60/172,226 18 September 1998 (18.09.98) US 60/131,321 27 April 1999 (27.04.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/172,226 (CIP) Filed on 18 September 1998 (18.09.98) US 60/131,321 (CIP) Filed on 27 April 1999 (27.04.99) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230		Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: HUMAN CYTOSKELETON ASSOCIATED PROTEINS (57) Abstract The invention provides human cytoskeleton associated proteins (CYSKP) and polynucleotides which identify and encode CYSKP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CYSKP.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN CYTOSKELETON ASSOCIATED PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human cytoskeleton associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, vesicle trafficking, neurological, cell motility, reproductive, and muscle disorders.

BACKGROUND OF THE INVENTION

The cytoskeleton, a cytoplasmic system of protein fibers, mediates cell shape, structure, and movement. The cytoskeleton supports the cell membrane and forms tracks along which organelles and other elements move in the cytosol. The cytoskeleton is a dynamic structure that allows cells to adopt various shapes and to carry out directed movements. Major cytoskeletal fibers are the microfilaments, the microtubules, and the intermediate filaments. Motor proteins, including myosin, dynein, and kinesin, drive movement of, or along, the fibers. The motor protein dynamin drives the formation of membrane vesicles. Accessory or associated proteins modify the structure or activity of the fibers while cytoskeletal membrane anchors connect the fibers to the cell membrane. (The cytoskeleton is reviewed in Lodish, H. et al. (1995) Molecular Cell Biology Scientific American Books, New York NY.)

Microtubules and Associated Proteins

Tubulins

Microtubules, cytoskeletal fibers with a diameter of 24 nm, have multiple roles in the cell. Bundles of microtubules form cilia and flagella, which are whip-like extensions of the cell membrane that are necessary for sweeping materials across an epithelium and for swimming of sperm, respectively. Marginal bands of microtubules in red blood cells and platelets are important for these cells' pliability. Organelles, membrane vesicles, and proteins are transported in the cell along tracks of microtubules. For example, microtubules run through nerve cell axons, allowing bi-directional transport of materials and membrane vesicles between the cell body and the nerve terminal. Failure to supply the nerve terminal with these vesicles blocks the transmission of neural signals. Microtubules, in the form of the spindle, are also critical to chromosomal movement during cell division. Both stable and short-lived populations of microtubules exist in the cell.

Microtubules are a polymer of GTP-binding tubulin protein subunits. Each subunit is a heterodimer of α - and β - tubulin, multiple isoforms of which exist. The hydrolysis of GTP is linked

to the addition of tubulin subunits at the end of a microtubule. The subunits interact head to tail to form protofilaments; the protofilaments interact side to side to form a microtubule. A microtubule is polarized, one end ringed with α -tubulin and the other with β -tubulin, and the two ends differ in their rates of assembly. Generally each microtubule is composed of 13 protofilaments although 11 or 15 protofilament-microtubules are sometimes found. Cilia and flagella contain doublet microtubules. Microtubules grow from specialized structures known as centrosomes or microtubule-organizing centers (MTOCs). MTOCs may contain one or two centrioles, which are pinwheel arrays of triplet microtubules. The basal body, the organizing center located at the base of a cilium or flagellum, contains one centriole. γ -tubulin present in the MTOC is important for nucleating the polymerization of α - and β -tubulin heterodimers but does not polymerize into microtubules. The protein pericentrin is found in the MTOC and has a role in microtubule assembly.

Microtubule-Associated Proteins

Microtubule-associated proteins (MAPs) have roles in the assembly and stabilization of microtubules. One major family of MAPs, assembly MAPs, can be identified in neurons as well as non-neuronal cells. Assembly MAPs are responsible for cross-linking microtubules in the cytosol. These MAPs are organized into two domains: a basic microtubule-binding domain and an acidic projection domain. The projection domain is the binding site for membranes, intermediate filaments, or other microtubules. Based on sequence analysis, assembly MAPs can be further grouped into two types: Type I and Type II.

Type I MAPs, which include MAP1A and MAP1B, are large, filamentous molecules that co-purify with microtubules and are abundantly expressed in brain and testis. They contain several repeats of a positively-charged amino acid sequence motif that binds and neutralizes negatively charged tubulin, leading to stabilization of microtubules. MAP1A and MAP1B are each derived from a single precursor polypeptide that is subsequently proteolytically processed to generate one heavy chain and one light chain.

Another light chain, LC3, is a 16.4 kDa molecule that binds MAP1A, MAP1B, and microtubules. It is suggested that LC3 is synthesized from a source other than the MAP1A or MAP1B transcripts, and the expression of LC3 may be important in regulating the microtubule binding activity of MAP1A and MAP1B during cell proliferation (Mann, S. S. et al. (1994) J. Biol. Chem. 269:11492-11497).

Type II MAPs, which include MAP2a, MAP2b, MAP2c, MAP4, and Tau, are characterized by three to four copies of an 18-residue sequence in the microtubule-binding domain. MAP2a, MAP2b, and MAP2c are found only in dendrites, MAP4 is found in non-neuronal cells, and Tau is found in axons and dendrites of nerve cells. Alternative splicing of the Tau mRNA leads to the

existence of multiple forms of Tau protein. Tau phosphorylation is altered in neurodegenerative disorders such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia and Parkinsonism linked to chromosome 17. The altered Tau phosphorylation leads to a collapse of the microtubule network and the formation of
 5 intraneuronal Tau aggregates (Spillantini, M.G. and Goedert, M. (1998) Trends Neurosci. 21:428-433).

Tektins are filamentous proteins that were originally discovered in association with axonemal microtubules of sea urchin sperm. Subsequent work has shown that tektins are also found in association with spindle microtubules in clams and in mammals. (Steffen, W. and Linck, R.W.
 10 (1992) J. Cell Sci. 101:809-822.) Tektins may form rod-like alpha-helical structures similar to those of intermediate filament proteins (Norrander, J.M. et al. (1996) J. Mol. Biol. 29:385-397).

Microtubular aggregates are associated with several disorders. An extraskelatal myxoid chondrosarcoma tumor from human contained parallel arrays of microtubules within the rough endoplasmic reticulum (Suzuki, T. et al. (1988) J. Pathol. 156:51-57). Microtubular aggregates were
 15 also found in hepatocytes from chimpanzees infected with hepatitis C virus. Monoclonal antibodies prepared to these aggregates detect a protein called p44 (or microtubular aggregates protein) (Maeda, T. et al. (1989) J. Gen. Virol. 70:1401-1407). A human homolog of p44 is inducible by interferon- α and interferon- β , but not by interferon- γ . p44 protein may be a mediator in the antiviral action of interferon (Kitamura, A. et al. (1994) Eur. J. Biochem. 224:877-883).

20 Dynein-related Motor Proteins

Dyneins are (-) end-directed motor proteins which act on microtubules. Two classes of dyneins exist, cytosolic and axonemal. Cytosolic dyneins are responsible for translocation of materials along cytoplasmic microtubules, for example, transport from the nerve terminal to the cell body and transport of endocytic vesicles to lysosomes. Cytoplasmic dyneins are also reported to play
 25 a role in mitosis. Axonemal dyneins are responsible for the beating of flagella and cilia. Dynein on one microtubule doublet walks along the adjacent microtubule doublet. This sliding force produces bending forces that cause the flagellum or cilium to beat. Dyneins have a native mass between 1000 and 2000 kDa and contain either two or three force-producing heads driven by the hydrolysis of ATP. The heads are linked via stalks to a basal domain which is composed of a highly variable number of
 30 accessory intermediate and light chains.

Microfilaments and Associated Proteins

Actins

Microfilaments, cytoskeletal filaments with a diameter of 7-9 nm, are vital to cell locomotion.

cell shape, cell adhesion, cell division, and muscle contraction. Assembly and disassembly of the microfilaments allow cells to change their morphology. Microfilaments are the polymerized form of actin, the most abundant intracellular protein in the eukaryotic cell. Human cells contain six isoforms of actin. The three α -actins are found in different kinds of muscle, nonmuscle β -actin and nonmuscle γ -actin are found in nonmuscle cells, and another γ -actin is found in intestinal smooth muscle cells. G-actin, the monomeric form of actin, polymerizes into polarized, helical F-actin filaments, accompanied by the hydrolysis of ATP to ADP. Actin filaments associate to form bundles and networks, providing a framework to support the plasma membrane and determine cell shape. These bundles and networks are connected to the cell membrane. In muscle cells, thin filaments containing actin slide past thick filaments containing the motor protein myosin during contraction. A family of actin-related proteins exist that are not part of the actin cytoskeleton, but rather associate with microtubules and dynein.

Actin-Associated Proteins

Actin-associated proteins have roles in cross-linking, severing, and stabilization of actin filaments and in sequestering actin monomers. Several of the actin-associated proteins have multiple functions. Bundles and networks of actin filaments are held together by actin cross-linking proteins. These proteins have two actin-binding sites, one for each filament. Short cross-linking proteins promote bundle formation while longer, more flexible cross-linking proteins promote network formation. Calmodulin-like calcium-binding domains in actin cross-linking proteins allow calcium regulation of cross-linking. Group I cross-linking proteins have unique actin-binding domains and include the 30 Kd protein, EF-1a, fascin, and scruin. Group II cross-linking proteins have a 7,000-MW actin-binding domain and include villin and dematin. Group III cross-linking proteins have pairs of a 26,000-MW actin-binding domain and include fimbrin, spectrin, dystrophin, ABP 120, and filamin.

Severing proteins regulate the length of actin filaments by breaking them into short pieces or by blocking their ends. Severing proteins include gCAP39, severin (fragmin), gelsolin, and villin. Capping proteins can cap the ends of actin filaments, but cannot break filaments. Capping proteins include CapZ, tropomodulin, and tensin.

Tensin, which is found in focal adhesions, also crosslinks actin filaments. Integrin activation by the extracellular matrix leads to the phosphorylation of tensin on tyrosine, serine, and threonine residues; this phosphorylation also occurs in cells transformed with oncogenes. Tensin has an SH2 domain and may bind to other tyrosine-phosphorylated proteins. (Lo, S.H. et al. (1997) *J. Cell Biol.* 136:1349-1361.) The N-terminus of tensin contains a region homologous to the catalytic domain of a putative tyrosine phosphatase (PTP) from *Saccharomyces cerevisiae*. This PTP domain in tensin may

mediate binding interactions with phosphorylated polypeptides (Haynie, D.T. and Ponting, C.P. (1996) *Protein Sci.* 5:2643-2646). Mice which lack the tensin gene have kidney abnormalities, indicating that the loss of tensin leads to weakening of focal adhesions in the kidney (Lo, *supra*).

The proteins thymosin and profilin sequester actin monomers in the cytosol, allowing a pool of unpolymerized actin to exist. Profilin may also stimulate F-actin formation by effectively lowering the critical concentration required for actin monomer addition (Gertler, F.B. et al. (1996) *Cell* 87:227-239).

The Ena/VASP (vasodilator-stimulated phosphoprotein) protein family has roles in actin-based motility. These proteins, including Mena, VASP, and Evl (Ena/VASP-like), have homology to the *Drosophila* Enabled protein which is involved in neural development. Mammalian Ena/VASP proteins localize at focal contacts and in regions where actin filaments are highly dynamic. The neural forms of Mena induce F-actin rich outgrowths in fibroblasts. Mena may have roles in microfilament-based extension of filopodia during axonal growth cone migration. *In vitro* motility assays of the intracellular pathogenic bacterium *Listeria monocytogenes* in platelet and brain extracts show that the Ena/VASP proteins play interchangeable roles in the transformation of actin polymerization into active movement and propulsive force. The Ena/VASP proteins associate with actin, profilin, the focal adhesion protein zyxin, and vinculin. Phosphorylation of Mena and VASP may regulate their activity. (Gertler, *supra*; Laurent, V. et al. (1999) *J. Cell Biol.* 144:1245-1258.)

The actin-associated proteins tropomyosin, troponin, and caldesmon regulate muscle contraction in response to calcium. The tropomyosin proteins, found in muscle and nonmuscle cells, are α -helical and form coiled-coil dimers. Striated muscle tropomyosin mediates the interactions between the troponin complex and actin, regulating muscle contraction. (PROSITE PDOC00290 Tropomyosins signature.) The troponin complex is composed of troponin-T, troponin-I, and troponin-C. Troponin-T binds tropomyosin, linking troponin-I and troponin-C to tropomyosin.

Intermediate Filaments and Associated Proteins

Intermediate filaments (IFs) are cytoskeletal fibers with a diameter of 10 nm, intermediate between that of microfilaments and microtubules. They serve structural roles in the cell, reinforcing cells and organizing cells into tissues. IFs are particularly abundant in epidermal cells and in neurons. IFs are extremely stable, and, in contrast to microfilaments and microtubules, do not function in cell motility. IF proteins include acidic keratins, basic keratins, desmin, glial fibrillary acidic protein, vimentin, peripherin, neurofilaments, nestin, and lamins.

IFs have a central α -helical rod region interrupted by short nonhelical linker segments. The rod region is bracketed, in most cases, by non-helical head and tail domains. The rod regions of

intermediate filament proteins associate to form a coiled-coil dimer. A highly ordered assembly process leads from the dimers to the IFs. Neither ATP nor GTP is needed for IF assembly, unlike that of microfilaments and microtubules.

IF-associated proteins (IFAPs) mediate the interactions of IFs with one another and with
5 other cell structures. IFAPs cross-link IFs into a bundle, into a network, or to the plasma membrane, and may cross-link IFs to the microfilament and microtubule cytoskeleton. Microtubules and IFs in particular are closely associated. IFAPs include BPAG1, plakoglobin, desmoplakin I, desmoplakin II, plectin, ankyrin, filaggrin, and lamin B receptor.

The N-terminal portion of ankyrin consists of a repeated 33-amino acid motif, the ankyrin
10 repeat, which is involved in specific protein-protein interactions. Variable regions within the motif are responsible for specific protein binding, such that different ankyrin repeats are involved in binding to tubulin, anion exchange protein, voltage-gated sodium channel, Na⁺/K⁺-ATPase, and neurofascin. The ankyrin motif is also found in transcription factors, such as NF- κ -B, and in the yeast cell cycle proteins CDC10, SW14, and SW16. Proteins involved in tissue differentiation, such
15 as *Drosophila* Notch and *C. elegans* LIN-12 and GLP-1, also contain ankyrin-like repeats. Lux et al. (1990; Nature 344:36-42) suggest that ankyrin-like repeats function as 'built-in' ankyrins and form binding sites for integral membrane proteins, tubulin, and other proteins.

Other Cytoskeleton-Associated Proteins

20 Some cytoskeleton-associated proteins contain a conserved, glycine-rich domain of about 42 residues. This domain, called CAP-Gly, is found in restin, a protein associated with intermediate filaments; vertebrate dynactin, which is associated with dynein; and yeast BIK1 protein which may be required for the formation or stabilization of microtubules during mitosis and for spindle pole body fusion during conjugation. (PROSITE PDOC00660 CAP-Gly domain signature.)

25

Proteins of the Erythrocyte Membrane Skeleton

Distribution of oxygen throughout the vertebrate body is effected by red blood cells (erythrocytes). Oxygen diffuses from surrounding water or from the atmosphere through either gill epithelium or pulmonary epithelial type I cells. Oxygen then diffuses through the blood capillary
30 endothelium directly to the blood circulatory system and through the erythrocyte membrane and is stored as soluble oxyhemoglobin in the cytoplasm. Oxygen is released from hemoglobin at sites throughout the organism and diffuses out from the erythrocyte to other target cells. The structure of the erythrocyte membrane as well as that of other non-erythrocyte cells must be maintained to enable efficient diffusion of oxygen to intracellular compartments.

The erythrocyte membrane is comprised of i) a cholesterol-rich phospholipid bilayer in which many trans-bilayer proteins are embedded, ii) external glycosylphosphatidylinositol-anchored proteins (GPI-proteins), and iii) the erythrocyte or membrane skeleton that laminates the inner surface of the bilayer. The trans-bilayer proteins include anion exchangers, glycophorins, glucose transporters, and a variety of cation transporters and pumps. The erythrocyte GPI-proteins include acetylcholinesterase and decay-accelerating factor (CD 55). The skeletal proteins are organized on the cortical, or cytoplasmic, face of the plasma membrane. These proteins include protein 4.1, protein p55, α - and β -spectrin, actin, and actin-binding proteins such as dematin, tropomyosin, and tropomodulin. α - and β -spectrin combine to form a heterotetramer in vivo. The spectrin heterotetramer organizes into a cortical bidimensional network with a hexagonal mesh. The network is linked to trans-bilayer proteins through a protein complex comprising β -spectrin, ankyrin, anion exchanger, and protein 4.2 and through the "triangular" interaction between protein 4.1, glycophorin C, and protein p55. Structural and functional variants of erythrocyte membrane proteins have been found in a variety of tissues. Variants may be transcribed from multigene families, e.g., anion exchanger, ankyrin, or spectrin, or from single gene families, e.g., protein 4.1 or protein 4.2. mRNA transcripts undergo tissue-specific alternative splicing. Many congenital hemolytic anemias result from mutations in the above-mentioned genes encoding erythrocyte membrane proteins. For example, hereditary elliptocytosis stems from an array of mutations in the spectrin genes at or near the head-to-head self-association region of the spectrin tetramer, or from mutations in the protein 4.1 gene which reduce levels of protein 4.1. In another example, hereditary spherocytosis is associated with mutations in the ankyrin gene, the anion exchanger gene, the protein 4.2 gene, or the α - and β -spectrin genes. (Delaunay J. (1995) *Transfus. Clin. Biol.* 2:207-216.)

Protein 4.1 is an 80 kDa erythrocyte membrane protein with four functional domains. These domains include: i) a 30 kDa basic N-terminal domain, homologous to the ERM (Ezrin/Radixin/Moesin) family of actin- and transmembrane protein-binding proteins (Tsukita, S. et al. (1997) *Trends Biochem. Sci.* 22:53-58); ii) a 16 kDa hydrophilic domain containing a protein kinase C phosphorylation site; iii) a 10 kDa highly charged domain containing a cAMP-dependent protein kinase phosphorylation site critical for the interaction with spectrin and actin; and iv) a 22/24 kDa acidic domain. Protein 4.1 is a member of a structurally and functionally related protein 4.1 family. The protein 4.1 family is part of an evolutionarily related protein superfamily that includes many tyrosine phosphatases. (Baklouti, F. et al. (1997) *Genomics* 39:289-302.)

In contrast to the strictly cortical localization of protein 4.1 in mature enucleate erythrocytes, protein 4.1 epitopes have been observed throughout the cytoplasmic compartment and the nucleoskeleton in nucleated cells. In particular, protein 4.1 is present in the nucleoskeleton during

interphase, in the mitotic spindle during mitosis, in perichromatin during telophase, and in the midbody during cytokinesis. (Krauss, S.W. et al. (1997) J. Cell Biol. 137:275-289.)

Differential expression of the protein 4.1 gene resulting in a number of mRNA splice variants has been observed in various human and rodent tissues. Comparison of the gene structure and mRNA
 5 splice variants revealed the extreme genomic sequence conservation of protein 4.1 between different species. The 5' UTR of both the human and rodent mRNA species has not been successfully identified and sequenced, possibly due to GC-rich regions therein which give rise to technical complications during nucleotide sequencing reactions. (Baklouti, supra; Conboy, J.G. (1988) Proc. Natl. Acad. Sci. 85:9062-9065.)

10 Analysis of proteins included in the ERM family of proteins has indicated that the N-terminal domain interacts with intracellular domains of transmembrane proteins such as CD44 and the C-terminal domain binds actin. Both interactions involve interactions with Rho-GTP protein complex, polyphosphoinositides, and serine/threonine kinase and tyrosine kinase activities. Many of the phosphorylation sites on ERM proteins are conserved. Although expression of ERM proteins in vivo
 15 is restricted to tissues such as endothelium, repression of ERM protein gene expression is released under conditions of cell culture. (Tsukita, supra.)

The cortical actin cytoskeleton participates in various membrane-based processes which necessitate a large amount of functional plasticity in the molecular components involved. A family of proteins homologous to band 4.1 is involved in the reorganization of the actin cytoskeleton in
 20 response to various stimuli and probably plays a role in transmembrane signaling. This family includes tyrosine phosphatases, substrates of tyrosine kinases and a candidate for a tumor-suppressor gene. (Arpin M, et al. (1994) Curr. Opin. Cell Biol. 6:136-141.)

Disruptions in cytoskeletal protein interaction have been identified in a number of disease conditions or disorders. Neurofibromatosis type 2 is an autosomal dominant disease of the nervous
 25 system. Schwann cells isolated from patients with neurofibromatosis type 2 have characteristic morphology and growth parameters which differ from control Schwann cells. A gene associated with neurofibromatosis type 2 has been identified and is termed NF2. The NF2 gene product, known as schwannomin or merlin, is a member of the protein 4.1 superfamily, and mutations in the NF2 gene have been shown to be associated with the disease. (Rosenbaum, C. et al. (1998) Neurobiol. Dis.
 30 5:55-64.) In addition, a form of psoriasis may be due to altered expression or distribution in epidermal epithelium of analogs of erythrocyte protein 4.1. (Shimizu, T. (1996) Histol. Histopathol. 11:495-501.) Erythrocytes carrying mutations in spectrin and protein 4.1 showed differing sensitivities to invasion by Plasmodium falciparum. (Facer, C.A. (1995) Parasitol Res. 81:52-57.) Furthermore, antibodies raised against erythrocyte protein 4.1 stained the majority of neurofibrillary

tangles in the prefrontal cortex and hippocampus of brain tissue from patients with Alzheimer's disease. A 68 kDa protein was identified as the most likely brain analog of erythrocyte protein 4.1. (Sihag, R.K. et al. (1994) Brain Res. 656:14-26.)

The discovery of new human cytoskeleton associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, vesicle trafficking, neurological, cell motility, reproductive, and muscle disorders.

SUMMARY OF THE INVENTION

10 The invention features substantially purified polypeptides, human cytoskeleton associated proteins, referred to collectively as "CYSKP" and individually as "CYSKP-1," "CYSKP-2," "CYSKP-3," "CYSKP-4," "CYSKP-5," "CYSKP-6," "CYSKP-7," "CYSKP-8," "CYSKP-9," "CYSKP-10," "CYSKP-11," "CYSKP-12," "CYSKP-13," "CYSKP-14," "CYSKP-15," and "CYSKP-16." In one aspect, the invention provides a substantially purified polypeptide comprising
15 an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof.

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-16 and fragments thereof. The invention also provides an isolated and purified polynucleotide
20 encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof.

25 Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence
30 selected from the group consisting of SEQ ID NO:1-16 and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the

hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32 and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-16 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of CYSKP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of CYSKP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding CYSKP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods and algorithms used for identification of CYSKP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding CYSKP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze CYSKP, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"CYSKP" refers to the amino acid sequences of substantially purified CYSKP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or
5 recombinant.

The term "agonist" refers to a molecule which, when bound to CYSKP, increases or prolongs the duration of the effect of CYSKP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of CYSKP.

An "allelic variant" is an alternative form of the gene encoding CYSKP. Allelic variants may
10 result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one
15 or more times in a given sequence.

"Altered" nucleic acid sequences encoding CYSKP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as CYSKP or a polypeptide with at least one functional characteristic of CYSKP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide
20 probe of the polynucleotide encoding CYSKP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding CYSKP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent CYSKP. Deliberate amino acid substitutions may be made on the basis of similarity in
25 polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of CYSKP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine;
30 asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of CYSKP which are preferably at least 5 to about 15 amino acids in

length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of CYSKP. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with
5 the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which, when bound to CYSKP, decreases the
10 amount or the duration of the effect of the biological or immunological activity of CYSKP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of CYSKP.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that
15 bind CYSKP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and
20 keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on
25 the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the
30 complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the

capability of the natural, recombinant, or synthetic CYSKP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the
5 complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which
10 depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.
15 Compositions comprising polynucleotide sequences encoding CYSKP or fragments of CYSKP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

20 "Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and
25 assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding CYSKP, by northern analysis is indicative of the presence of nucleic acids encoding CYSKP in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding CYSKP.

30 A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide

encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

5 The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization
10 assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to
15 one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

20 The phrases "percent identity" and "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) *Gene* 73:237-244.) Parameters
25 for each method may be the default parameters provided by MEGALIGN or may be specified by the user. The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in
30 sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 183:626-645.) Identity between sequences can also be determined

by other methods known in the art, e.g., by varying hybridization conditions.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

5 The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

10 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_{0t} or R_{0t} analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate
15 to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune
20 disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable
25 polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of CYSKP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of CYSKP.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a nucleotide,
30 oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:17-32, for example, as

distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:17-32 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:17-32 from related polynucleotide sequences. A fragment of SEQ ID NO:17-32 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:17-32 and the region of SEQ ID NO:17-32 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" and "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding CYSKP, or fragments thereof, or CYSKP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the

antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of CYSKP polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to CYSKP. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species.

Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

THE INVENTION

The invention is based on the discovery of new human cytoskeleton associated proteins (CYSKP), the polynucleotides encoding CYSKP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, vesicle trafficking, neurological, cell motility, reproductive, and muscle disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding CYSKP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each CYSKP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The clones in column 5 were used to assemble the consensus nucleotide sequence of each CYSKP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding CYSKP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These

fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:17-32 and to distinguish between SEQ ID NO:17-32 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express CYSKP as a fraction of total tissues expressing CYSKP. 5 Column 4 lists diseases, disorders, or conditions associated with those tissues expressing CYSKP as a fraction of total tissues expressing CYSKP. Column 5 lists the vectors used to subclone each cDNA library.

Of particular note is the expression of SEQ ID NO:31 in nervous tissues and the expression of SEQ ID NO:32 in musculoskeletal tissues.

10 The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding CYSKP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses CYSKP variants. A preferred CYSKP variant is one which 15 has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the CYSKP amino acid sequence, and which contains at least one functional or structural characteristic of CYSKP.

The invention also encompasses polynucleotides which encode CYSKP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected 20 from the group consisting of SEQ ID NO:17-32, which encodes CYSKP.

The invention also encompasses a variant of a polynucleotide sequence encoding CYSKP. In particular, such a variant polynucleotide sequence will have at least about 70%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding CYSKP. A particular aspect of the invention encompasses a 25 variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:17-32 which has at least about 70%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:17-32. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural 30 characteristic of CYSKP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding CYSKP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide

sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring CYSKP, and all such variations are to be considered as being specifically disclosed.

5 Although nucleotide sequences which encode CYSKP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring CYSKP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding CYSKP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the
10 peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding CYSKP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

15 The invention also encompasses production of DNA sequences which encode CYSKP and CYSKP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding CYSKP or any fragment thereof.

20 Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:17-32 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM
25 NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily
30 include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment,

hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding CYSKP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences,

such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown
5 sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction
10 enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries
15 and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

20 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

25 Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate
30 software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof

which encode CYSKP may be cloned in recombinant DNA molecules that direct expression of CYSKP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express CYSKP.

5 The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter CYSKP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-
10 mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding CYSKP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 7:215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 7:225-232.)
15 Alternatively, CYSKP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of CYSKP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other
20 proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH
25 Freeman, New York NY.)

In order to express a biologically active CYSKP, the nucleotide sequences encoding CYSKP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers,
30 constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding CYSKP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding CYSKP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding CYSKP and its initiation codon and

upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and
5 initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding CYSKP and appropriate transcriptional and translational
10 control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

15 A variety of expression vector/host systems may be utilized to contain and express sequences encoding CYSKP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower
20 mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding CYSKP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding CYSKP can be achieved using a
25 multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies). Ligation of sequences encoding CYSKP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for
30 in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of CYSKP are needed, e.g. for the production of antibodies, vectors which direct high level expression of CYSKP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of CYSKP. A number of vectors

containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 5 1995, supra; Grant et al. (1987) *Methods Enzymol.* 153:516-54; and Scorer, C. A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of CYSKP. Transcription of sequences encoding CYSKP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 10 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology 15 (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding CYSKP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain 20 infective virus which expresses CYSKP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of 25 DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression 30 of CYSKP in cell lines is preferred. For example, sequences encoding CYSKP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to

confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These
5 include, but are not limited to, the herpes simplex virus thymidine kinase and adenine
phosphoribosyltransferase genes, for use in *tk* or *ap^r* cells, respectively. (See, e.g., Wigler, M. et al.
(1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or
herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to
methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* or *pat*
10 confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g.,
Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J.
Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which
alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc.
Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins
15 (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate
luciferin may be used. These markers can be used not only to identify transformants, but also to
quantify the amount of transient or stable protein expression attributable to a specific vector system.
(See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is
20 also present, the presence and expression of the gene may need to be confirmed. For example, if the
sequence encoding CYSKP is inserted within a marker gene sequence, transformed cells containing
sequences encoding CYSKP can be identified by the absence of marker gene function. Alternatively,
a marker gene can be placed in tandem with a sequence encoding CYSKP under the control of a
single promoter. Expression of the marker gene in response to induction or selection usually
25 indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding CYSKP and that
express CYSKP may be identified by a variety of procedures known to those of skill in the art. These
procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR
amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or
30 chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of CYSKP using either
specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques
include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and
fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing

monoclonal antibodies reactive to two non-interfering epitopes on CYSKP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding CYSKP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding CYSKP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding CYSKP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode CYSKP may be designed to contain signal sequences which direct secretion of CYSKP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid

sequences encoding CYSKP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric CYSKP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of CYSKP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the CYSKP encoding sequence and the heterologous protein sequence, so that CYSKP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled CYSKP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably ³⁵S-methionine.

Fragments of CYSKP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of CYSKP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of CYSKP and human cytoskeleton associated proteins. In addition, the expression of CYSKP is closely associated with cancer, cell proliferation, inflammation, immune response, musculoskeletal, nervous, reproductive, cardiovascular, and gastrointestinal tissues. Therefore, CYSKP appears to play a role in cell proliferative, autoimmune/inflammatory, vesicle trafficking,

neurological, cell motility, reproductive, and muscle disorders. In the treatment of disorders associated with increased CYSKP expression or activity, it is desirable to decrease the expression or activity of CYSKP. In the treatment of disorders associated with decreased CYSKP expression or activity, it is desirable to increase the expression or activity of CYSKP.

- 5 Therefore, in one embodiment, CYSKP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CYSKP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria,
- 10 polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory
- 15 disorder such as acquired immunodeficiency syndrome (AIDS), actinic keratosis, Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis,
- 20 diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, mixed connective tissue disease (MCTD), myelofibrosis, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis,
- 25 polycythemia vera, polymyositis, primary thrombocythemia, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a vesicle trafficking disorder such
- 30 as cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, diabetes mellitus, diabetes insipidus, hyper- and hypoglycemia, Grave's disease, goiter, Cushing's disease, and Addison's disease, gastrointestinal disorders including ulcerative colitis, gastric and duodenal ulcers, other conditions associated with abnormal vesicle trafficking, including acquired immunodeficiency syndrome (AIDS), allergies including hay fever, asthma, and urticaria (hives), autoimmune hemolytic

- anemia, proliferative glomerulonephritis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, rheumatoid and osteoarthritis, scleroderma, Chediak-Higashi and Sjogren's syndromes, systemic lupus erythematosus, toxic shock syndrome, traumatic tissue damage, and viral, bacterial, fungal, helminthic, and protozoal infections; a neurological disorder such as epilepsy, ischemic
- 5 cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral
- 10 meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy,
- 15 neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy,
- 20 tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cell motility disorder such as ankylosing spondylitis, Chediak-Higashi syndrome, Duchenne and Becker muscular dystrophy, intrahepatic cholestasis, myocardial hyperplasia, cardiomyopathy, early onset periodontitis, cancers such as adenocarcinoma, ovarian carcinoma, and chronic myelogenous
- 25 leukemia, and bacterial and helminthic infections; and a heart and skeletal muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic myopathy, and ethanol myopathy.

- 30 In another embodiment, a vector capable of expressing CYSKP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CYSKP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified CYSKP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat

or prevent a disorder associated with decreased expression or activity of CYSKP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of CYSKP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CYSKP including, but not limited to, those listed above.

In a further embodiment, an antagonist of CYSKP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CYSKP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, vesicle trafficking, neurological, cell motility, and heart and skeletal muscle disorders described above; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis, cancer of the breast, fibrocystic breast disease, and galactorrhea, a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; and a smooth muscle disorder. A smooth muscle disorder is defined as any impairment or alteration in the normal action of smooth muscle and may include, but is not limited to, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma, and myopathies including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia. Smooth muscle includes, but is not limited to, that of the blood vessels, gastrointestinal tract, heart, and uterus. In one aspect, an antibody which specifically binds CYSKP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express CYSKP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding CYSKP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CYSKP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic

efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of CYSKP may be produced using methods which are generally known in the art. In particular, purified CYSKP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind CYSKP. Antibodies to CYSKP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with CYSKP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to CYSKP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of CYSKP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to CYSKP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce CYSKP-specific single

chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte
5 population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for CYSKP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin
10 digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired
15 specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between CYSKP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering CYSKP epitopes is preferred, but a competitive binding assay may
20 also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for CYSKP. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of CYSKP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.
25 The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple CYSKP epitopes, represents the average affinity, or avidity, of the antibodies for CYSKP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular CYSKP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in
30 which the CYSKP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of CYSKP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to

Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of CYSKP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding CYSKP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding CYSKP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding CYSKP. Thus, complementary molecules or fragments may be used to modulate CYSKP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding CYSKP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding CYSKP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding CYSKP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding CYSKP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding CYSKP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful

because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding CYSKP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding CYSKP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

10 An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of CYSKP, antibodies to CYSKP, and mimetics, agonists, antagonists, or inhibitors of CYSKP. The compositions may be administered alone or in combination with at least one other agent, such as a
15 stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial,
20 intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on
25 techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees,
30 capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol,

and sorbitol: starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding

free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate
5 container and labeled for treatment of an indicated condition. For administration of CYSKP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

10 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

15 A therapeutically effective dose refers to that amount of active ingredient, for example CYSKP or fragments thereof, antibodies of CYSKP, and agonists, antagonists or inhibitors of CYSKP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the
20 dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with
25 little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the
30 severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind CYSKP may be used for the diagnosis of disorders characterized by expression of CYSKP, or in assays to monitor patients being treated with CYSKP or agonists, antagonists, or inhibitors of CYSKP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for CYSKP include methods which utilize the antibody and a label to detect CYSKP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring CYSKP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of CYSKP expression. Normal or standard values for CYSKP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to CYSKP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of CYSKP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding CYSKP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of CYSKP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of CYSKP, and to monitor regulation of CYSKP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CYSKP or closely related molecules may be used to identify nucleic acid sequences which encode CYSKP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a

conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding CYSKP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the CYSKP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:17-32 or from genomic sequences including promoters, enhancers, and introns of the CYSKP gene.

Means for producing specific hybridization probes for DNAs encoding CYSKP include the cloning of polynucleotide sequences encoding CYSKP or CYSKP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding CYSKP may be used for the diagnosis of disorders associated with expression of CYSKP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), actinic keratosis, Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, mixed connective tissue disease (MCTD), myelofibrosis, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, primary

thrombocythemia, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and

5 trauma; a vesicle trafficking disorder such as cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, diabetes mellitus, diabetes insipidus, hyper- and hypoglycemia, Grave's disease, goiter, Cushing's disease, and Addison's disease, gastrointestinal disorders including ulcerative colitis, gastric and duodenal ulcers, other conditions associated with abnormal vesicle trafficking, including acquired immunodeficiency syndrome (AIDS), allergies including hay fever,

10 asthma, and urticaria (hives), autoimmune hemolytic anemia, proliferative glomerulonephritis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, rheumatoid and osteoarthritis, scleroderma, Chediak-Higashi and Sjogren's syndromes, systemic lupus erythematosus, toxic shock syndrome, traumatic tissue damage, and viral, bacterial, fungal, helminthic, and protozoal infections; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral

15 neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central

20 nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial

25 nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic

30 neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cell motility disorder such as ankylosing spondylitis, Chediak-Higashi syndrome, Duchenne and Becker muscular dystrophy, intrahepatic cholestasis, myocardial hyperplasia, cardiomyopathy, early onset periodontitis, cancers such as adenocarcinoma, ovarian carcinoma, and chronic myelogenous leukemia, and bacterial and helminthic infections; a heart and

skeletal muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic myopathy, and ethanol myopathy; a

5 reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea, a disruption of spermatogenesis, abnormal sperm

10 physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; and a smooth muscle disorder. A smooth muscle disorder is defined as any impairment or alteration in the normal action of smooth muscle and may include, but is not limited to, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial

15 infarction, migraine, and pheochromocytoma, and myopathies including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia. Smooth muscle includes, but is not limited to, that of the blood vessels, gastrointestinal tract, heart, and uterus. The polynucleotide sequences encoding CYSKP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR

20 technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered CYSKP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding CYSKP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide

25 sequences encoding CYSKP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding CYSKP in the

30 sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of CYSKP, a normal or standard profile for expression is established. This may be accomplished by

combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding CYSKP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding CYSKP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding CYSKP, or a fragment of a polynucleotide complementary to the polynucleotide encoding CYSKP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of CYSKP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify

genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding CYSKP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent *in situ* hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, *supra*, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding CYSKP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion,

etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, CYSKP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between CYSKP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with CYSKP, or fragments thereof, and washed. Bound CYSKP is then detected by methods well known in the art. Purified CYSKP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding CYSKP specifically compete with a test compound for binding CYSKP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with CYSKP.

In additional embodiments, the nucleotide sequences which encode CYSKP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/131,321, and [Atty Docket No. PF-0594 P, filed September 18, 1998] are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XLI-Blue, XLI-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8

Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) *Anal. Biochem.* 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

10 III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default

parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:17-32. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel, 1995, *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules

are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding CYSKP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of CYSKP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:17-32 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar,

Acton MA). allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending
5 the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviII cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%)
10 agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-
15 well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was
20 quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

25 In like manner, the nucleotide sequences of SEQ ID NO:17-32 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:17-32 are employed to screen cDNAs,
30 genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase
35 (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a

SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

5 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography and compared.

10 VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand
15 or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

20 Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an
25 appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

30 VIII. Complementary Polynucleotides

Sequences complementary to the CYSKP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring CYSKP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are
35 designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of CYSKP. To

inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the CYSKP-encoding transcript.

5 IX. Expression of CYSKP

Expression and purification of CYSKP is achieved using bacterial or virus-based expression systems. For expression of CYSKP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid
10 promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express CYSKP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of CYSKP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus
15 (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding CYSKP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
20 Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, CYSKP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step,
25 affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from CYSKP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity
30 purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified CYSKP obtained by these methods can be used directly in the following activity assay.

35 X. Demonstration of CYSKP Activity

A microtubule motility assay for CYSKP activity measures motor domain function. In this assay, recombinant CYSKP is immobilized onto a glass slide or similar substrate. Taxol-stabilized bovine brain microtubules (commercially available) in a solution containing ATP and cytosolic extract are perfused onto the slide. Movement of microtubules as driven by CYSKP motor activity can be visualized and quantified using video-enhanced light microscopy and image analysis techniques. CYSKP activity is directly proportional to the frequency and velocity of microtubule movement.

In the alternative, an assay for CYSKP measures the binding affinity of CYSKP for actin as described by Hammell, R.L. and Hitchcock-DeGregori, S.E. (1997, J. Biol. Chem. 272:22409-22416). CYSKP and actin are prepared from *in vitro* recombinant cDNA expression systems and the N-terminus of CYSKP is acetylated using methods well known in the art. Binding of N-terminal acetyl-CYSKP to actin is measured by cosedimentation at 25°C in a Beckman model TL-100 centrifuge as described. The bound and free CYSKP are determined by quantitative densitometry of SDS-polyacrylamide gels stained with Coomassie Blue. Apparent binding constants (K_{app}) and Hill coefficients (H) are determined by using methods well known in the art to fit the data to the equation as described by Hammell and Hitchcock-DeGregori (1997, *supra*). The CYSKP:actin ratio, determined using densitometry, is normalized. Hammell and Hitchcock-DeGregori (1997, *supra*) have shown that saturation of binding corresponds to a CYSKP:actin molar ratio of 0.14, a stoichiometry of 1 CYSKP:7 actin. The binding of CYSKP to actin is proportional to the CYSKP activity.

In the alternative, CYSKP are assayed by their ability to bind to F-actin using a blot overlay system similar to that described by Luna, E.J. et al. (1997, Soc. Gen. Physiol. Ser. 52:3-18). Proteins in plasma membrane-enriched cell extracts containing CYSKP are separated using SDS polyacrylamide gel electrophoresis (10% acrylamide). The gel-separated proteins are transferred to nitrocellulose using methods well known in the art and the blot is washed and pretreated with non-specific blocking agents. [125 I]-labeled F-actin is prepared and suspended in overlay buffer, then incubated with the blot for at least 16 hours at 4°C. Unbound label is washed with washing buffer, the blot is air dried and subjected to autoradiography for at least one hour. The autoradiograph band corresponding to the expected molecular mass of CYSKP is identified. The amount of observed [125 I]-labeled F-actin which binds to CYSKP is proportional to the amount of CYSKP present in the sample.

In the alternative, CYSKP activity is associated with its ability to form protein-protein complexes and is measured by its ability to regulate growth characteristics of NIH3T3 mouse fibroblast cells. A cDNA encoding CYSKP is subcloned into an appropriate eukaryotic expression vector. This vector is transfected into NIH3T3 cells using methods known in the art. Transfected

cells are compared with non-transfected cells for the following quantifiable properties: growth in culture to high density, reduced attachment of cells to the substrate, altered cell morphology, and ability to induce tumors when injected into immunodeficient mice. The activity of CYSKP is proportional to the extent of increased growth or frequency of altered cell morphology in NIH3T3

5 cells transfected with CYSKP.

In the alternative, CYSKP activity is measured as ability to bind to microtubules.

Microtubules are purified from adult rat brain by reversible assembly (Vallee, R. B. (1982) *Methods Enzymol.* 134:89-104) or the taxol method (Vallee, R. B. (1982) *J. Cell Biol.* 92:435-442) using PEM buffer (100 mM PIPES, pH 6.6, 1mM EGTA, 1mM MgSO_4). To separate the MAPs from tubulin, 10 the pellets from twice-cycled microtubules are resuspended in PEM buffer and applied to a 0.1 M MgSO_4 -saturated phosphocellulose column as described by Sloboda, R. D. and Rosenbaum, J. L. ((1982) *Methods Enzymol.* 85:409-416). The fractions containing protein are applied to a second phosphocellulose column. In a total volume of 100 ml, 20 ml of CYSKP (250 mg/ml) is added to 80 ml of whole microtubules (450 mg/ml) or tubulin (300 mg/ml) and incubated at 37 °C for 10 minutes 15 in the presence of 1 mM GTP and 50 mM taxol. The suspension is centrifuged, the supernatant is removed, and the microtubule pellet is resuspended to the original reaction volume in PEM buffer. To assess the partitioning of CYSKP between the supernatant and pellet fractions, equal amounts of supernatant and resuspended pellet are placed in SDS sample buffer and assayed on a 5-20% gradient SDS polyacrylamide gel stained with Coomassie Brilliant Blue. The amount of CYSKP in the pellet 20 fraction is proportional to the binding of CYSKP to microtubules.

In the alternative, CYSKP, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled CYSKP, washed, and any wells with labeled CYSKP complex are assayed. Data obtained using different 25 concentrations of CYSKP are used to calculate values for the number, affinity, and association of CYSKP with the candidate molecules.

XI. Functional Assays

CYSKP function is assessed by expressing the sequences encoding CYSKP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a 30 mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing 35 sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a

means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of CYSKP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding CYSKP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding CYSKP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of CYSKP Specific Antibodies

CYSKP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the CYSKP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by,

for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring CYSKP Using Specific Antibodies

Naturally occurring or recombinant CYSKP is substantially purified by immunoaffinity chromatography using antibodies specific for CYSKP. An immunoaffinity column is constructed by covalently coupling anti-CYSKP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing CYSKP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of CYSKP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/CYSKP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and CYSKP is collected.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	17	1285395	COLNNOT16	015834R1 (HUELFPB01), 866407T1 (BRAITUT03), 1232405F6 (LUNGFET03), 1285395H1 (COLNNOT16), 1478554T1 (CORPNOT02), 2103609R6 (BRAITUT02), 2254859R6 (OVRTUT01), 2692529H1 (LUNGNOT23), 2959263H1 (ADRENOT09), 3076303H2 (BONEUNT01), 3367129H1 (CONNTUT04), 3855643H1 (BRAITUT12), 4061729H1 (BRAINT02), 4082537F6 (CONFNOT02)
2	18	1320252	BLADNOT04	229546R1 (PANCNOT01), 743845R6 (BRAITUT01), 826714T1 (PROSNOT06), 864534R1 (BRAITUT03), 997163R2 (KIDNTUT01), 1320252F6 and 1320252H1 (BLADNOT04), 1349551F1 (LATRTUT02), 1441011F1 (THYRNOT03), 1500649F6 (SINTBST01), 1525416T1 (UCMCL5T01), 1928370R6 (BRSTNOT02), 1932270H1 (COLNNOT16), 3213480F6 (BLADNOT08), 4540043H1 (THYRTMT01)
3	19	1259001	MENITUT03	1259001H1 (MENITUT03), 1550766H1 (PROSNOT06), 1594658F1 (BRAINT04), 1594658T1 (BRAINT04), 1653882F6 (PROSTUT08), 1864111F6 (PROSNOT19), 3399605H1 (UTRSNOT16), 3677286H1 (PLACNOT07), 5045012H1 (PLACFER01), 5188326H1 (LUNGWTW04), SATA00218F1, SATA00850F1
4	20	1627027	COLNPOT01	1361332F6 (LUNGNOT12), 1933148H1 (COLNNOT16), 2378239F6 (ISLTNUT01), 2378239T6 (ISLTNUT01), 3433415H1 (PENCNOT05), 3433415X303F1 (PENCNOT05), 4453336H1 (HEAADIR01)
5	21	1905315	OVARNOT07	1504617F1 (BRAITUT07), 1520641F1 (BLADTUT04), 1905315H1 (OVARNOT07), 3282914F6 (HEAONOT05), 3282914T6 (HEAONOT05)
6	22	1997789	BRSTTUT03	833978T1 (PROSNOT07), 1309235R1 (COLNFET02), 1659579F6 (URETTUT01), 1734634T6 (COLNNOT22), 2930134F6 (TLYMNOT04), SAEA00063F1
7	23	2303465	BRSTNOT05	411540R6 (BRSTNOT01), 487448F1 (HNT2AGT01), 487448R1 (HNT2AGT01), 647107H1 (BRSTTUT02), 1426319F1 (SINTBST01), 2155735F6 (BRAINT09), 2155735T6 (BRAINT09), 2303465H1 (BRSTNOT05)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
8	24	2363178	LUNGFET05	2363178H1 (LUNGFET05), 2590354F6 (LUNGNOT22), 2590354T6 (LUNGNOT22)
9	25	2363327	ADRENOT07	013068R6 (THPLPB01), 1295235H1 (PGANNOT03), 1445845X13 (PLACNOT02), 1472260R6 (LUNGNOT03), 1474238T6 (LUNGNOT03), 1643970F6 (HEAREFET01), 1794319R6 (PROSTUT05), 1868517F6 (SKINBIT01), 2057830R6 (BEPINOT01), 2058164H1 (BEPINOT01), 2363327F6 (ADRENOT07), 2363327H1 (ADRENOT07), 2363327T6 (ADRENOT07), 2877024F6 (THYRNOT10), 2877024T6 (THYRNOT10), 2930751F6 (TLYMNOT04), 3002267F6 (TLYMNOT06)
10	26	2508327	CONUTUT01	2508327H1 (CONUTUT01), 2508327T6 (CONUTUT01), 3743046H1 (THYMNOT08)
11	27	2524555	BRAITUT21	781951H1 (MYOMNOT01), 2524555H1 (BRAITUT21), 3243902H1 (BRAINOT19), 4296903H1 (SCOMDIT01), SAEA01358F1
12	28	2900717	DRGCNOT01	933857R1 (CERVNOT01), 1632793T6 (COLNNOT19), 1909014F6 (CONNTUT01), 2250618R6 (OVARUTUT01), 2900717F6 (DRGCNOT01), 2900717H1 (DRGCNOT01), 2967545H1 (SCORNOT04), 3506152H1 (ADRENOT11), 4713710H1 (BRAIHCT01)
13	29	3088904	HEAONOT03	990189H1 (COLNNOT11), 2530228H1 (GBLANOT02), 3088904F6 (HEAONOT03), 3088904H1 (HEAONOT03), 3176845T6 (UTRSTUT04)
14	30	3745193	THYMNOT08	2775454H1 (PANCNOT15), 2811439H1 (OVARNOT10), 3745193F6 (THYMNOT08), 3745193H1 (THYMNOT08), 3745193T6 (THYMNOT08)
15	31	3822123	BONSTUT01	736132R6 (TONSNOT01), 1856649F6 (PROSNOT18), 1877413F6 (LEUKNOT03), 3395569T6 (LUNGNOT28), 3577567H1 (BRONNOT01), 3822123H1 (BONSTUT01), 4247960H1 (BRABDIT01)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
16	32	4217506	ADRENOT15	590362R1 (UTRSNOT01), 973313R6 (MUSCNOT02), 4216992H1 (ADRENOT15), SEJA03360F1

Table 2

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequences	Analytical Methods
1	1005	S15 T194 S402 S548 S614 T673 S7 S39 S151 S159 T180 T223 T530 S647 S658 S682 T730 S744 S746 S748 T766 S828 S854 T879 S890 T952 S58 S208 T212 S323 T381 S449 S518 S543 S544 S884 T944 Y623	N36	L225 to F263 W272 to D300 I321 to Q367 H379 to L408 F440 to K458 S718 to G721	protein 4.1	BLAST ProfileScan PFAM BLOCKS PRINTS
2	1045	T92 S270 S366 S23 T150 T207 T396 S418 T448 T525 S549 S571 S706 T811 S815 S840 S842 S872 S878 T883 S889 T898 S923 S966 S987 S1038 S36 S41 S336 S340 T343 S370 S408 T538 T551 S657 S658 S770 T789 T826 S839 Y542	N152 N495 N919	L47 to F85 W94 to D123 L144 to D190 I196 to I249 F261 to K279 S770 to G773	protein 4.1	BLAST ProfileScan PFAM BLOCKS PRINTS

Table 2 (cont.)

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequences	Analytical Methods
3	324	T71 T78 S121 S123 S225 T259 S283 T304 S144 S150 S181 T249 S273 S276 S289	N151 N180	Ankyrin repeat: P6-A41; D42-E74; G76-K85	ARF-directed GTPase activating protein (ankyrin-repeat containing, involved in regulation of cytoskeletal organization) (Mus musculus) g4063614	BLAST PFAM BLOCKS_PFAM
4	385	T6 T30 T375 T19 S61 S161 S176	N59 N132 N328 N341		cardiac muscle tensin (Gallus gallus) g619577	BLAST
5	364	T65 T74 T79 S80 T139 T151 T228 T244 T276 T9 T79 T349 Y116	N318		similar to alpha- actinin (Caenorhabditis elegans) g2315828	BLAST
6	395	S158 S94 S130 S213 S214 S251 S283 S296 S348 T19 S20 T46 S121 T250 S285	N62 N317	WASP homology domain 1: M1-L109	ena-VASP like protein (Mus musculus) g1644453	PFAM BLAST

Table 2 (cont.)

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequences	Analytical Methods
7	523	T213 S140 T157 S215 T245 S251 S286 S516 T518 S57 T342 S398 S405 S427 S453 S483 T484 T503 Y103 Y197 Y297	N410	ATP/GTP-binding site motif A (P loop): G74-T82	dynein light chain A (Gallus sp.) g510249	MOTIFS BLAST
8	348	S32 S55 T104 T153 T183 S213 T223 T249 S34 S41 T51 T52 S166 S293	N86 N164 N233	Tektin signature: R119-E139	tektin C1 [Strongylocentrotus purpuratus] g1353490	PRINTS BLAST
9	731	S117 S136 S162 T168 S219 S249 S390 T451 S665 S694 S15 T292 S313 T559 S703 Y131 Y407 Y490	N125 N134 N205 N551	CAP-Gly domain proteins: G40-C64		BLOCKS
10	147	T100 S137 S138 S9 Y86 Y116	N91		light chain 3 subunit of microtubule- associated proteins 1A and 1B (Rattus norvegicus) g455109	BLAST

Table 2 (cont.)

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequences	Analytical Methods
11	57	T13 S15		Thymosin beta-4 family: S15-G55	thymosin beta-4 (Mus musculus) g54794	PFAM MOTIFS ProfileScan BLOCKS BLAST
12	452	T8 S36 S75 T94 S117 S237 S246 S311 T358 S406 T4 S208 S216 T239 S295 Y188	N21 N80 N91 N373	ATP/GTP-binding site motif A (P loop): G204-S211 Signal peptide: M1-G34	non-A non-B hepatitis- associated microtubular aggregates protein (p44) (pan troglodytes) g218576	MOTIFS SPSCAN BLAST
13	281	T76 T50 S60 S207 S212 T213 T234 T249 S259 T274 S120 S155		Tropomyosins: K6-E38; K45-L281	beta-tropomyosin (Mus musculus) g192157	MOTIFS PFAM ProfileScan BLOCKS BLAST
14	92	S16 S23 T45 T60 T71 T85 T78		Tropomyosin: M1-M92	tropomyosin 5 TM-5 (Rattus sp.) g1703676	PFAM ProfileScan BLOCKS BLAST

Table 2 (cont.)

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Homologous Sequences	Analytical Methods
15	448	T126 T73 T94 S165 T193 S287 S439 T82 S241 T337 Y172	N380	Tubulin: M1-E433 Signal peptide: M1-A32	alpha-tubulin isotype M-alpha-6 [Mus musculus] g202215	MOTIFS PFAM BLOCKS SPSCAN
16	269	T181 S2 T40 S88 S244 T241 S253	N164	Troponin: K73-W215; H252-K269	troponin T fast muscle isoform [Mus musculus] g2340062	PFAM BLOCKS..PFAM BLAST

Table 3

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
17	549-587	Nervous (0.265) Reproductive (0.229) Cardiovascular (0.145)	Cancer (0.482) Inflammation (0.253)	pINCY
18	882-918	Reproductive (0.220) Nervous (0.207) Gastrointestinal (0.134)	Cancer (0.549) Trauma (0.110) Inflammation (0.098)	pINCY
19	817-864	Reproductive (0.372) Nervous (0.186) Gastrointestinal (0.116)	Cancer and Cell Proliferation (0.651) Inflammation and Immune Response (0.256)	pINCY
20	489-533	Gastrointestinal (0.385) Cardiovascular (0.154) Reproductive (0.154)	Cancer and Cell Proliferation (0.385) Inflammation and Immune Response (0.308)	pINCY
21	50-106	Reproductive (0.220) Hematopoietic/Immune (0.200) Cardiovascular (0.140)	Cancer and Cell Proliferation (0.500) Inflammation and Immune Response (0.360)	pINCY
22	1070-1228	Hematopoietic/Immune (0.211) Reproductive (0.186) Nervous (0.180)	Cancer and Cell Proliferation (0.590) Inflammation and Immune Response (0.360)	PSPORT1
23	250-336	Reproductive (0.291) Gastrointestinal (0.163) Cardiovascular (0.116) Nervous (0.116)	Cancer and Cell Proliferation (0.663) Inflammation and Immune Response (0.337)	PSPORT1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
24	164-208	Cardiovascular (0.333) Developmental (0.333) Reproductive (0.333)	Inflammation and Immune Response (0.500) Cancer and Cell Proliferation (0.500)	PSPORT1
25	1028-1072	Hematopoietic/Immune (0.286) Reproductive (0.159) Nervous (0.127)	Cancer and Cell Proliferation (0.540) Inflammation and Immune Response (0.413)	pINCY
26	397-516	Gastrointestinal (0.333) Hematopoietic/Immune (0.333) Musculoskeletal (0.333)	Cancer and Cell Proliferation (0.667)	pINCY
27	434-541	Reproductive (0.236) Nervous (0.156) Gastrointestinal (0.148)	Cancer and Cell Proliferation (0.575) Inflammation and Immune Response (0.353)	pINCY
28	1-177	Reproductive (0.269) Hematopoietic/Immune (0.192) Nervous (0.192)	Cancer and Cell Proliferation (0.654) Inflammation and Immune Response (0.462)	pINCY
29		Reproductive (0.339) Gastrointestinal (0.191) Cardiovascular (0.114)	Cancer and Cell Proliferation (0.631) Inflammation and Immune Response (0.288)	pINCY
30	488-532 551-649	Reproductive (0.199) Gastrointestinal (0.144) Nervous (0.144)	Cancer and Cell Proliferation (0.580) Inflammation and Immune Response (0.326)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
31	163-207	Nervous (0.305) Reproductive (0.158) Gastrointestinal (0.137)	Cancer and Cell Proliferation (0.547) Inflammation and Immune Response (0.295)	pINCY
32	99-143	Musculoskeletal (0.280) Developmental (0.160) Reproductive (0.160)	Cancer and Cell Proliferation (0.680) Inflammation and Immune Response (0.280)	pINCY

Table 4

Polynucleotide SEQ ID NO:	Library	Library Comment
17	COLNNOT16	Library was constructed using RNA isolated from sigmoid colon tissue removed from a 62-year-old Caucasian male during a sigmoidectomy and permanent colectomy. Pathology for the associated tumor tissue indicated invasive grade 2 adenocarcinoma, with invasion through the muscularis. One lymph node contained metastasis with extranodal extension. Family history included benign hypertension, atherosclerotic coronary artery disease, breast cancer, and prostate cancer.
18	BLADNOT04	Library was constructed using RNA isolated from bladder tissue of a 28-year-old Caucasian male, who died from a self-inflicted gunshot wound. The patient had a history of alcohol and tobacco use.
19	MENITUT03	Library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer.
20	COLNPOT01	Library was constructed using RNA isolated from colon polyp tissue removed from a 40-year-old Caucasian female during a total colectomy. Pathology indicated an inflammatory pseudopolyp; this tissue was associated with a focally invasive grade 2 adenocarcinoma and multiple tubovillous adenomas. Patient history included a benign neoplasm of the bowel.
21	OVARNOT07	Library was constructed using RNA isolated from left ovarian tissue removed from a 28-year-old Caucasian female during a vaginal hysterectomy and removal of the fallopian tubes and ovaries. The tissue was associated with multiple follicular cysts, endometrium in a weakly proliferative phase, and chronic cervicitis of the cervix with squamous metaplasia. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease.

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Comment
22	BRSTTUT03	Library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.
23	BRSTNOT05	Library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes.
24	LUNGFET05	Library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation from anencephalus.
25	ADRENOT07	Library was constructed using RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands.
26	CONUTUT01	Library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed müllerian tumor present in the sigmoid mesentery at two sites.

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Comment
27	BRAITUT21	Library was constructed using RNA isolated from brain tumor tissue removed from the midline frontal lobe of a 61-year-old Caucasian female during excision of a cerebral meningioma. Pathology indicated subfrontal meningothelial meningioma with no atypia. One ethmoid and mucosal tissue sample indicated meningioma. Family history included cerebrovascular disease, senile dementia, hyperlipidemia, benign hypertension, atherosclerotic coronary artery disease, congestive heart failure, and breast cancer.
28	DRGCNOT01	Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.
29	HEAONOT03	Library was constructed using RNA isolated from aortic tissue removed from a 27-year-old Caucasian female, who died from an intracranial bleed.
30	THYMNOT08	Library was constructed using RNA isolated from thymus tissue removed from a 4-month-old Caucasian male during a total thymectomy and open heart repair of atrioventricular canal defect using hypothermia. The patient presented with a congenital heart anomaly, congestive heart failure, and Down syndrome. Patient history included abnormal thyroid function study and premature birth. Previous procedures included right and left heart angiography.
31	BONSTUT01	Library was constructed using RNA isolated from sacral bone tumor tissue removed from an 18-year-old Caucasian female during an exploratory laparotomy with soft tissue excision. Pathology indicated giant cell tumor of the sacrum. Patient history included a soft tissue malignant neoplasm. Family history included prostate cancer.

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Library	Library Comment
32	ADRENOT15	Library was constructed using RNA isolated from adrenal tissue removed from a Caucasian female fetus, who died from anencephalus after 16-weeks' gestation.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <51%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, tfasta, tfasta, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.0E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fasta E value=1.0E-8 or less Full Length sequences: fasta score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Altmood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger, and Probability value= 1.0E-3 or less if applicable
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) <i>J. Mol. Biol.</i> 215:403-410; Altschul, S.F. et al. (1997) <i>Nucleic Acids Res.</i> 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) <i>Proc. Natl. Acad. Sci.</i> 85:2444-2448; Pearson, W.R. (1990) <i>Methods Enzymol.</i> 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) <i>Adv. Appl. Math.</i> 2:482-489.	ESTs: fasta E value= 1.0E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater: fasta E value= 1.0E-8 or less Full Length sequences: fasta score= 100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff, <i>Nucl. Acid Res.</i> , 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) <i>Methods Enzymol.</i> 266:88-105; and Althwood, T.K. et al. (1997) <i>J. Chem. Inf. Comput. Sci.</i> 37: 417-424.	Score= 1000 or greater, Ratio of Score/Strength = 0.75 or larger, and Probability value= 1.0E-3 or less if applicable
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) <i>J. Mol. Biol.</i> , 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) <i>Nucleic Acids Res.</i> 26:320-322.	Score= 10-50 bits, depending on individual protein families

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and fragments thereof.
2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
- 10 3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
- 15 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary
20 to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - 25 (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
- 30 9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and
35 fragments thereof.

10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.
11. An isolated and purified polynucleotide having a sequence which is complementary
5 to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
- 10 14. A method for producing a polypeptide, the method comprising the steps of:
a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
b) recovering the polypeptide from the host cell culture.
- 15 15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
- 20 16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
18. A purified antagonist of the polypeptide of claim 1.
- 25 19. A method for treating or preventing a disorder associated with decreased expression or activity of CYSKP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.
- 30 20. A method for treating or preventing a disorder associated with increased expression or activity of CYSKP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

LAL, Preeti

TANG, Y. Tom

YUE, Henry

HILLMAN, Jennifer L.

BANDMAN, Olga

CORLEY, Neil C.

GUEGLER, Karl J.

PATTERSON, Chandra

AZIMZAI, Yalda

BAUGHN, Mariah R.

<120> HUMAN CYTOSKELETON ASSOCIATED PROTEINS

<130> PF-0594 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/156,470; unassigned; 60/131,321

<151> 1998-09-18; 1998-09-18; 1999-04-27

<160> 32

<170> PERL Program

<210> 1

<211> 1005

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1285395

<400> 1

Met	Thr	Thr	Glu	Val	Gly	Ser	Val	Ser	Glu	Val	Lys	Lys	Asp	Ser	
1				5					10					15	
Ser	Gln	Leu	Gly	Thr	Asp	Ala	Thr	Lys	Glu	Lys	Pro	Lys	Glu	Val	
				20					25					30	
Ala	Glu	Asn	Gln	Gln	Asn	Gln	Ser	Ser	Asp	Pro	Glu	Glu	Glu	Lys	
				35					40					45	
Gly	Ser	Gln	Pro	Pro	Pro	Ala	Ala	Glu	Ser	Gln	Ser	Ser	Leu	Arg	
				50					55					60	
Arg	Gln	Lys	Arg	Glu	Lys	Glu	Thr	Ser	Glu	Ser	Arg	Gly	Ile	Ser	
				65					70					75	
Arg	Phe	Ile	Pro	Pro	Trp	Leu	Lys	Lys	Gln	Lys	Ser	Tyr	Thr	Leu	
				80					85					90	
Val	Val	Ala	Lys	Asp	Gly	Gly	Asp	Lys	Lys	Glu	Pro	Thr	Gln	Ala	
				95					100					105	
Val	Val	Glu	Glu	Gln	Val	Leu	Asp	Lys	Glu	Glu	Pro	Leu	Pro	Glu	
				110					115					120	

Glu Gln Arg Gln Ala Lys Gly Asp Ala Glu Glu Met Ala Gln Lys
 125 130 135
 Lys Gln Glu Ile Lys Val Glu Val Lys Glu Glu Lys Pro Ser Val
 140 145 150
 Ser Lys Glu Glu Lys Pro Ser Val Ser Lys Val Glu Met Gln Pro
 155 160 165
 Thr Glu Leu Val Ser Lys Glu Arg Glu Glu Lys Val Lys Glu Thr
 170 175 180
 Gln Glu Asp Lys Leu Glu Gly Gly Ala Ala Lys Arg Glu Thr Lys
 185 190 195
 Glu Val Gln Thr Asn Glu Leu Lys Ala Glu Lys Ala Ser Gln Lys
 200 205 210
 Val Thr Lys Lys Thr Lys Thr Val Gln Cys Lys Val Thr Leu Leu
 215 220 225
 Asp Gly Thr Glu Tyr Ser Cys Asp Leu Glu Lys His Ala Lys Gly
 230 235 240
 Gln Val Leu Phe Asp Lys Val Cys Glu His Leu Asn Leu Leu Glu
 245 250 255
 Lys Asp Tyr Phe Gly Leu Leu Phe Gln Glu Ser Pro Glu Gln Lys
 260 265 270
 Asn Trp Leu Asp Pro Ala Lys Glu Ile Lys Arg Gln Leu Arg Asn
 275 280 285
 Leu Pro Trp Leu Phe Thr Phe Asn Val Lys Phe Tyr Pro Pro Asp
 290 295 300
 Pro Ser Gln Leu Thr Glu Asp Ile Thr Arg Tyr Phe Leu Cys Leu
 305 310 315
 Gln Leu Arg Gln Asp Ile Ala Ser Gly Arg Leu Pro Cys Ser Phe
 320 325 330
 Val Thr His Ala Leu Leu Gly Ser Tyr Thr Leu Gln Ala Glu Leu
 335 340 345
 Gly Asp Tyr Asp Pro Glu Glu His Gly Ser Ile Asp Leu Ser Glu
 350 355 360
 Phe Gln Phe Ala Pro Thr Gln Thr Lys Glu Leu Glu Glu Lys Val
 365 370 375
 Ala Glu Leu His Lys Thr His Arg Gly Leu Ser Pro Ala Gln Ala
 380 385 390
 Asp Ser Gln Phe Leu Glu Asn Ala Lys Arg Leu Ser Met Tyr Gly
 395 400 405
 Val Asp Leu His His Ala Lys Asp Ser Glu Gly Val Asp Ile Lys
 410 415 420
 Leu Gly Val Cys Ala Asn Gly Leu Leu Ile Tyr Lys Asp Arg Leu
 425 430 435
 Arg Ile Asn Arg Phe Ala Trp Pro Lys Ile Leu Lys Ile Ser Tyr
 440 445 450
 Lys Arg Ser Asn Phe Tyr Ile Lys Val Arg Pro Ala Glu Leu Glu
 455 460 465
 Gln Phe Glu Ser Thr Ile Gly Phe Lys Leu Pro Asn His Arg Ala
 470 475 480
 Ala Lys Arg Leu Trp Lys Val Cys Val Glu His His Thr Phe Tyr
 485 490 495
 Arg Leu Val Ser Pro Glu Gln Pro Pro Lys Ala Lys Phe Leu Thr
 500 505 510
 Leu Gly Ser Lys Phe Arg Tyr Ser Gly Arg Thr Gln Ala Gln Thr
 515 520 525
 Arg Gln Ala Ser Thr Leu Ile Asp Arg Pro Ala Pro His Phe Glu

530	535	540
Arg Thr Ser Ser Lys Arg Val Ser Arg Ser Leu Asp Gly Ala Pro		
545	550	555
Ile Gly Val Met Asp Gln Ser Leu Met Lys Asp Phe Pro Gly Ala		
560	565	570
Ala Gly Glu Ile Ser Ala Tyr Gly Pro Gly Leu Val Ser Ile Ala		
575	580	585
Val Val Gln Asp Gly Asp Gly Arg Arg Glu Val Arg Ser Pro Thr		
590	595	600
Lys Ala Pro His Leu Gln Leu Ile Glu Gly Lys Lys Asn Ser Leu		
605	610	615
Arg Val Glu Gly Asp Asn Ile Tyr Val Arg His Ser Asn Leu Met		
620	625	630
Leu Glu Glu Leu Asp Lys Ala Gln Glu Asp Ile Leu Lys His Gln		
635	640	645
Ala Ser Ile Ser Glu Leu Lys Arg Asn Phe Met Glu Ser Thr Pro		
650	655	660
Glu Pro Arg Pro Asn Glu Trp Glu Lys Arg Arg Ile Thr Pro Leu		
665	670	675
Ser Leu Gln Thr Gln Gly Ser Ser His Glu Thr Leu Asn Ile Val		
680	685	690
Glu Glu Lys Lys Arg Ala Glu Val Gly Lys Asp Glu Arg Val Ile		
695	700	705
Thr Glu Glu Met Asn Gly Lys Glu Ile Ser Pro Gly Ser Gly Pro		
710	715	720
Gly Glu Ile Arg Lys Val Glu Pro Val Thr Gln Lys Asp Ser Thr		
725	730	735
Ser Leu Ser Ser Glu Ser Ser Ser Ser Ser Ser Glu Ser Glu Glu		
740	745	750
Glu Asp Val Gly Glu Tyr Arg Pro His His Arg Val Thr Glu Gly		
755	760	765
Thr Ile Arg Glu Glu Gln Glu Tyr Glu Glu Glu Val Glu Glu Glu		
770	775	780
Pro Arg Pro Ala Ala Lys Val Val Glu Arg Glu Glu Ala Val Pro		
785	790	795
Glu Ala Ser Pro Val Thr Gln Ala Gly Ala Ser Val Ile Thr Val		
800	805	810
Glu Thr Val Ile Gln Glu Asn Val Gly Ala Gln Lys Ile Pro Gly		
815	820	825
Glu Lys Ser Val His Glu Gly Ala Leu Lys Gln Asp Met Gly Glu		
830	835	840
Glu Ala Glu Glu Glu Pro Gln Lys Val Asn Gly Glu Val Ser His		
845	850	855
Val Asp Ile Asp Val Leu Pro Gln Ile Ile Cys Cys Ser Glu Pro		
860	865	870
Pro Val Val Lys Thr Glu Met Val Thr Ile Ser Asp Ala Ser Gln		
875	880	885
Arg Thr Glu Ile Ser Thr Lys Glu Val Pro Ile Val Gln Thr Glu		
890	895	900
Thr Lys Thr Ile Thr Tyr Glu Ser Pro Gln Ile Asp Gly Gly Ala		
905	910	915
Gly Gly Asp Ser Gly Thr Leu Leu Thr Ala Gln Thr Ile Thr Ser		
920	925	930
Glu Ser Val Ser Thr Thr Thr Thr Thr His Ile Thr Lys Thr Val		
935	940	945

Lys Gly Gly Ile Ser Glu Thr Arg Ile Glu Lys Arg Ile Val Ile
 950 955 960
 Thr Gly Asp Gly Asp Ile Asp His Asp Gln Ala Leu Ala Gln Ala
 965 970 975
 Ile Arg Glu Ala Arg Glu Gln His Pro Asp Met Ser Val Thr Arg
 980 985 990
 Val Val Val His Lys Glu Thr Glu Leu Ala Glu Glu Gly Glu Asp
 995 1000 1005

<210> 2

<211> 1045

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1320252

<400> 2

Met Gly Glu Ile Glu Gln Arg Pro Thr Pro Gly Ser Arg Leu Gly
 1 5 10 15
 Ala Pro Glu Asn Ser Gly Ile Ser Thr Leu Glu Arg Gly Gln Lys
 20 25 30
 Pro Pro Pro Thr Pro Ser Gly Lys Leu Val Ser Ile Lys Ile Gln
 35 40 45
 Met Leu Asp Asp Thr Gln Glu Ala Phe Glu Val Pro Gln Arg Ala
 50 55 60
 Pro Gly Lys Val Leu Leu Asp Ala Val Cys Asn His Leu Asn Leu
 65 70 75
 Val Glu Gly Asp Tyr Phe Gly Leu Glu Phe Pro Asp His Lys Lys
 80 85 90
 Ile Thr Val Trp Leu Asp Leu Leu Lys Pro Ile Val Lys Gln Ile
 95 100 105
 Arg Arg Pro Lys His Val Val Val Lys Phe Val Val Lys Phe Phe
 110 115 120
 Pro Pro Asp His Thr Gln Leu Gln Glu Glu Leu Thr Arg Tyr Leu
 125 130 135
 Phe Ala Leu Gln Val Lys Gln Asp Leu Ala Gln Gly Arg Leu Thr
 140 145 150
 Cys Asn Asp Thr Ser Ala Ala Leu Leu Ile Ser His Ile Val Gln
 155 160 165
 Ser Glu Ile Gly Asp Phe Asp Glu Ala Leu Asp Arg Glu His Leu
 170 175 180
 Ala Lys Asn Lys Tyr Ile Pro Gln Gln Asp Ala Leu Glu Asp Lys
 185 190 195
 Ile Val Glu Phe His His Asn His Ile Gly Gln Thr Pro Ala Glu
 200 205 210
 Ser Asp Phe Gln Leu Leu Glu Ile Ala Arg Arg Leu Glu Met Tyr
 215 220 225
 Gly Ile Arg Leu His Pro Ala Lys Asp Arg Glu Gly Thr Lys Ile
 230 235 240
 Asn Leu Ala Val Ala Asn Thr Gly Ile Leu Val Phe Gln Gly Phe
 245 250 255
 Thr Lys Ile Asn Ala Phe Asn Trp Ala Lys Val Arg Lys Leu Ser

260	265	270
Phe Lys Arg Lys Arg Phe Phe Ile Lys	Leu Arg Pro Asp Ala Asn	
275	280	285
Ser Ala Tyr Gln Asp Thr Leu Glu Phe	Leu Met Ala Ser Arg Asp	
290	295	300
Phe Cys Lys Ser Phe Trp Lys Ile Cys	Val Glu His His Ala Phe	
305	310	315
Phe Arg Leu Phe Glu Glu Pro Lys Pro	Lys Pro Lys Pro Val Leu	
320	325	330
Phe Ser Arg Gly Ser Ser Phe Arg Phe	Ser Gly Arg Thr Gln Lys	
335	340	345
Gln Val Leu Asp Tyr Val Lys Glu Gly	Gly His Lys Lys Val Gln	
350	355	360
Phe Glu Arg Lys His Ser Lys Ile His	Ser Ile Arg Ser Leu Ala	
365	370	375
Ser Gln Pro Thr Glu Leu Asn Ser Glu	Val Leu Glu Gln Ser Gln	
380	385	390
Gln Ser Thr Ser Leu Thr Phe Gly Glu	Gly Ala Glu Ser Pro Gly	
395	400	405
Gly Gln Ser Cys Arg Arg Gly Lys Glu	Pro Lys Val Ser Ala Gly	
410	415	420
Glu Pro Gly Ser His Pro Ser Pro Ala	Pro Arg Arg Ser Pro Ala	
425	430	435
Gly Asn Lys Gln Ala Asp Gly Ala Ala	Ser Ala Pro Thr Glu Glu	
440	445	450
Glu Glu Glu Val Val Lys Asp Arg Thr	Gln Gln Ser Lys Pro Gln	
455	460	465
Pro Pro Gln Pro Ser Thr Gly Ser Leu	Thr Gly Ser Pro His Leu	
470	475	480
Ser Glu Leu Ser Val Asn Ser Gln Gly	Gly Val Ala Pro Ala Asn	
485	490	495
Val Thr Leu Ser Pro Asn Leu Ser Pro	Asp Thr Lys Gln Ala Ser	
500	505	510
Pro Leu Ile Ser Pro Leu Leu Asn Asp	Gln Ala Cys Pro Arg Thr	
515	520	525
Asp Asp Glu Asp Glu Gly Arg Arg Lys	Arg Phe Pro Thr Asp Lys	
530	535	540
Ala Tyr Phe Ile Ala Lys Glu Val Ser	Thr Thr Glu Arg Thr Tyr	
545	550	555
Leu Lys Asp Leu Glu Val Ile Thr Ser	Trp Phe Gln Ser Thr Val	
560	565	570
Ser Lys Glu Asp Ala Met Pro Glu Ala	Leu Lys Ser Leu Ile Phe	
575	580	585
Pro Asn Phe Glu Pro Leu His Lys Phe	His Thr Asn Phe Leu Lys	
590	595	600
Glu Ile Glu Gln Arg Leu Ala Leu Trp	Glu Gly Arg Ser Asn Ala	
605	610	615
Gln Ile Arg Asp Tyr Gln Arg Ile Gly	Asp Val Met Leu Lys Asn	
620	625	630
Ile Gln Gly Met Lys His Leu Ala Ala	His Leu Trp Lys His Ser	
635	640	645
Glu Ala Leu Glu Ala Leu Glu Asn Gly	Ile Lys Ser Ser Arg Arg	
650	655	660
Leu Glu Asn Phe Cys Arg Asp Phe Glu	Leu Gln Lys Val Cys Tyr	
665	670	675

Leu Pro Leu Asn Thr Phe Leu Leu Arg Pro Leu His Arg Leu Met		
	680	685 690
His Tyr Lys Gln Val Leu Glu Arg Leu Cys Lys His His Pro Pro	695	700 705
Ser His Ala Asp Phe Arg Asp Cys Arg Ala Ala Leu Ala Glu Ile	710	715 720
Thr Glu Met Val Ala Gln Leu His Gly Thr Met Ile Lys Met Glu	725	730 735
Asn Phe Gln Lys Leu His Glu Leu Lys Lys Asp Leu Ile Gly Ile	740	745 750
Asp Asn Leu Val Val Pro Gly Arg Glu Phe Ile Arg Leu Gly Ser	755	760 765
Leu Ser Lys Leu Ser Gly Lys Gly Leu Gln Gln Arg Met Phe Phe	770	775 780
Leu Phe Asn Asp Val Leu Leu Tyr Thr Ser Arg Gly Leu Thr Ala	785	790 795
Ser Asn Gln Phe Lys Val His Gly Gln Leu Pro Leu Tyr Gly Met	800	805 810
Thr Ile Glu Glu Ser Glu Asp Glu Trp Gly Val Pro His Cys Leu	815	820 825
Thr Leu Arg Gly Gln Arg Gln Ser Ile Ile Val Ala Ala Ser Ser	830	835 840
Arg Ser Glu Met Glu Lys Trp Val Glu Asp Ile Gln Met Ala Ile	845	850 855
Asp Leu Ala Glu Lys Ser Ser Ser Pro Ala Pro Glu Phe Leu Ala	860	865 870
Ser Ser Pro Pro Asp Asn Lys Ser Pro Asp Glu Ala Thr Ala Ala	875	880 885
Asp Gln Glu Ser Glu Asp Asp Leu Ser Ala Ser Arg Thr Ser Leu	890	895 900
Glu Arg Gln Ala Pro His Arg Gly Asn Thr Met Val His Val Cys	905	910 915
Trp His Arg Asn Thr Ser Val Ser Met Val Asp Phe Ser Ile Ala	920	925 930
Val Glu Asn Gln Leu Ser Gly Asn Leu Leu Arg Lys Phe Lys Asn	935	940 945
Ser Asn Gly Trp Gln Lys Leu Trp Val Val Phe Thr Asn Phe Cys	950	955 960
Leu Phe Phe Tyr Lys Ser His Gln Asp Asn His Pro Leu Ala Ser	965	970 975
Leu Pro Leu Leu Gly Tyr Ser Leu Thr Ile Pro Ser Glu Ser Glu	980	985 990
Asn Ile Gln Lys Asp Tyr Val Phe Lys Leu His Phe Lys Ser His	995	1000 1005
Val Tyr Tyr Phe Arg Ala Glu Ser Glu Tyr Thr Phe Glu Arg Trp	1010	1015 1020
Met Glu Val Ile Arg Ser Ala Thr Ser Ser Ala Ser Arg Pro His	1025	1030 1035
Val Leu Ser His Lys Glu Ser Leu Val Tyr	1040	1045

<210> 3
 <211> 324
 <212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1259001

<400> 3

```

Met Cys Phe Gln Ala Pro Glu Glu Leu Val Leu His Leu Ala Val
  1          5          10          15
Lys Val Ala Asn Gln Ala Ser Leu Pro Leu Val Asp Phe Ile Ile
          20          25          30
Gln Asn Gly Gly His Leu Asp Ala Lys Ala Ala Asp Gly Asn Thr
          35          40          45
Ala Leu His Tyr Ala Ala Leu Tyr Asn Gln Pro Asp Cys Leu Lys
          50          55          60
Leu Leu Leu Lys Gly Arg Ala Leu Val Gly Thr Val Asn Glu Ala
          65          70          75
Gly Glu Thr Ala Leu Asp Ile Ala Arg Lys Lys His His Lys Glu
          80          85          90
Cys Glu Glu Leu Leu Glu Gln Ala Gln Ala Gly Thr Phe Ala Phe
          95          100          105
Pro Leu His Val Asp Tyr Ser Trp Val Ile Ser Thr Glu Pro Gly
          110          115          120
Ser Asp Ser Glu Glu Asp Glu Glu Glu Lys Arg Cys Leu Leu Lys
          125          130          135
Leu Pro Ala Gln Ala His Trp Ala Ser Gly Arg Leu Asp Ile Ser
          140          145          150
Asn Lys Thr Tyr Glu Thr Val Ala Ser Leu Gly Ala Ala Thr Pro
          155          160          165
Gln Gly Glu Ser Glu Asp Cys Pro Pro Pro Leu Pro Val Lys Asn
          170          175          180
Ser Ser Arg Thr Leu Val Gln Gly Cys Ala Arg His Ala Ser Gly
          185          190          195
Asp Arg Ser Glu Val Ser Ser Leu Ser Ser Glu Ala Pro Glu Thr
          200          205          210
Pro Glu Ser Leu Gly Ser Pro Ala Ser Ser Ser Ser Leu Met Ser
          215          220          225
Pro Leu Glu Pro Gly Asp Pro Ser Gln Ala Pro Pro Asn Ser Glu
          230          235          240
Glu Gly Leu Arg Glu Pro Pro Gly Thr Ser Arg Pro Ser Leu Thr
          245          250          255
Ser Gly Thr Thr Pro Ser Glu Met Tyr Leu Pro Val Arg Phe Ser
          260          265          270
Ser Glu Ser Thr Arg Ser Tyr Arg Arg Gly Ala Arg Ser Pro Glu
          275          280          285
Asp Gly Pro Ser Ala Arg Gln Pro Leu Pro Arg Arg Asn Val Pro
          290          295          300
Val Gly Ile Thr Glu Gly Asp Gly Ser Arg Thr Gly Ser Leu Pro
          305          310          315
Ala Ser Ser Val Gln Leu Leu Gln Asp
          320

```

<210> 4
 <211> 385
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1627027

<400> 4
 Met Ser Val Ser Arg Thr Met Glu Asp Ser Cys Glu Leu Asp Leu
 1 5 10 15
 Val Tyr Val Thr Glu Arg Ile Ile Ala Val Ser Phe Pro Ser Thr
 20 25 30
 Ala Asn Glu Glu Phe Arg Ser Asn Leu Arg Glu Val Ala Gln
 35 40 45
 Met Leu Lys Ser Lys His Gly Gly Asn Tyr Leu Leu Phe Asn Leu
 50 55 60
 Ser Glu Arg Arg Pro Asp Ile Thr Lys Leu His Ala Lys Val Leu
 65 70 75
 Glu Phe Gly Trp Pro Asp Leu His Thr Pro Ala Leu Glu Lys Ile
 80 85 90
 Cys Ser Ile Cys Lys Ala Met Asp Thr Trp Leu Asn Ala Asp Pro
 95 100 105
 His Asn Val Val Val Leu His Asn Lys Gly Asn Arg Gly Arg Ile
 110 115 120
 Gly Val Val Ile Ala Ala Tyr Met His Tyr Ser Asn Ile Ser Ala
 125 130 135
 Ser Ala Asp Gln Ala Leu Asp Arg Phe Ala Met Lys Arg Phe Tyr
 140 145 150
 Glu Asp Lys Ile Val Pro Ile Gly Gln Pro Ser Gln Arg Arg Tyr
 155 160 165
 Val His Tyr Phe Ser Gly Leu Leu Ser Gly Ser Ile Lys Met Asn
 170 175 180
 Asn Lys Pro Leu Phe Leu His His Val Ile Met His Gly Ile Pro
 185 190 195
 Asn Phe Glu Ser Lys Gly Gly Cys Arg Pro Phe Leu Arg Ile Tyr
 200 205 210
 Gln Ala Met Gln Pro Val Tyr Thr Ser Gly Ile Tyr Asn Ile Pro
 215 220 225
 Gly Asp Ser Gln Thr Ser Val Cys Ile Thr Ile Glu Pro Gly Leu
 230 235 240
 Leu Leu Lys Gly Asp Ile Leu Leu Lys Cys Tyr His Lys Lys Phe
 245 250 255
 Arg Ser Pro Ala Arg Asp Val Ile Phe Arg Val Gln Phe His Thr
 260 265 270
 Cys Ala Ile His Asp Leu Gly Val Val Phe Gly Lys Glu Asp Leu
 275 280 285
 Asp Asp Ala Phe Lys Asp Asp Arg Phe Pro Glu Tyr Gly Lys Val
 290 295 300
 Glu Phe Val Phe Ser Tyr Gly Pro Glu Lys Ile Gln Gly Met Glu
 305 310 315
 His Leu Glu Asn Gly Pro Ser Val Ser Val Asp Tyr Asn Thr Ser
 320 325 330
 Asp Pro Leu Ile Arg Trp Asp Ser Tyr Asp Asn Phe Ser Gly His

	335		340		345
Arg Asp Asp Gly Met Glu Asp Gly Asn Lys Gln Asn Thr Asn Ser					
	350		355		360
Gln Ser Ile Gly Ser Ile Ser Gly Gly Leu Glu Asp Gln Tyr Thr					
	365		370		375
Trp Pro Asp Thr His Trp Pro Ser Gln Ser					
	380		385		

<210> 5

<211> 364

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1905315

<400> 5

Met Ser Ser Ala Pro Arg Ser Pro Thr Pro Arg Pro Arg Arg Met		
1	5	10
Lys Lys Asp Glu Ser Phe Leu Gly Lys Leu Gly Gly Thr Leu Ala		
	20	25
Arg Lys Arg Arg Ala Arg Glu Val Ser Asp Leu Gln Glu Glu Gly		
	35	40
Lys Asn Ala Ile Asn Ser Pro Met Ser Pro Ala Leu Ala Asp Val		
	50	55
His Pro Glu Asp Thr Gln Leu Glu Glu Asn Glu Glu Arg Thr Met		
	65	70
Ile Asp Pro Thr Ser Lys Glu Asp Pro Lys Phe Lys Glu Leu Val		
	80	85
Lys Val Leu Leu Asp Trp Ile Asn Asp Val Leu Val Glu Glu Arg		
	95	100
Ile Ile Val Lys Gln Leu Glu Glu Asp Leu Tyr Asp Gly Gln Val		
	110	115
Leu Gln Lys Leu Leu Glu Lys Leu Ala Gly Cys Lys Leu Asn Val		
	125	130
Ala Glu Val Thr Gln Ser Glu Ile Gly Gln Lys Gln Lys Leu Gln		
	140	145
Thr Val Leu Glu Ala Val His Asp Leu Leu Arg Pro Arg Gly Trp		
	155	160
Ala Leu Arg Trp Ser Val Asp Ser Ile His Gly Lys Asn Leu Val		
	170	175
Ala Ile Leu His Leu Leu Val Ser Leu Ala Met His Phe Arg Ala		
	185	190
Pro Ile Arg Leu Pro Glu His Val Thr Val Gln Val Val Val Val		
	200	205
Arg Lys Arg Glu Gly Leu Leu His Ser Ser His Ile Ser Glu Glu		
	215	220
Leu Thr Thr Thr Thr Glu Met Met Met Gly Arg Phe Glu Arg Asp		
	230	235
Ala Phe Asp Thr Leu Phe Asp His Ala Pro Asp Lys Leu Ser Val		
	245	250
Val Lys Lys Ser Leu Ile Thr Phe Val Asn Lys His Leu Asn Lys		
	260	265
		270

```

Leu Asn Leu Glu Val Thr Glu Leu Glu Thr Gln Phe Ala Asp Gly
275                                280                                285
Val Tyr Leu Val Leu Leu Met Gly Leu Leu Glu Asp Tyr Phe Val
290                                295                                300
Pro Leu His His Phe Tyr Leu Thr Pro Glu Ser Phe Asp Gln Lys
305                                310                                315
Val His Asn Val Ser Phe Ala Phe Glu Leu Met Leu Asp Gly Gly
320                                325                                330
Leu Lys Lys Pro Lys Ala Arg Pro Glu Asp Val Val Asn Leu Asp
335                                340                                345
Leu Lys Ser Thr Leu Arg Val Leu Tyr Asn Leu Phe Thr Lys Tyr
350                                355                                360
Lys Asn Val Glu

```

<210> 6

<211> 395

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1997789

<400> 6

```

Met Ser Glu Gln Ser Ile Cys Gln Ala Arg Ala Ser Val Met Val
1          5          10          15
Tyr Asp Asp Thr Ser Lys Lys Trp Val Pro Ile Lys Pro Gly Gln
20          25          30
Gln Gly Phe Ser Arg Ile Asn Ile Tyr His Asn Thr Ala Ser Asn
35          40          45
Thr Phe Arg Val Val Gly Val Lys Leu Gln Asp Gln Gln Val Val
50          55          60
Ile Asn Tyr Ser Ile Val Lys Gly Leu Lys Tyr Asn Gln Ala Thr
65          70          75
Pro Thr Phe His Gln Trp Arg Asp Ala Arg Gln Val Tyr Gly Leu
80          85          90
Asn Phe Ala Ser Lys Glu Glu Ala Thr Thr Phe Ser Asn Ala Met
95          100         105
Leu Phe Ala Leu Asn Ile Met Asn Ser Gln Glu Gly Gly Pro Ser
110         115         120
Ser Gln Arg Gln Val Gln Asn Gly Pro Ser Pro Asp Glu Met Asp
125         130         135
Ile Gln Arg Arg Gln Val Met Glu Gln His Gln Gln Gln Arg Gln
140         145         150
Glu Ser Leu Glu Arg Arg Thr Ser Ala Thr Gly Pro Ile Leu Pro
155         160         165
Pro Gly His Pro Ser Ser Ala Ala Ser Ala Pro Val Ser Cys Ser
170         175         180
Gly Pro Pro Pro Pro Pro Pro Leu Val Pro Pro Pro Pro Thr
185         190         195
Gly Ala Thr Pro Pro Pro Pro Pro Leu Pro Ala Gly Gly Ala
200         205         210
Gln Gly Ser Ser His Asp Glu Ser Ser Met Ser Gly Leu Ala Ala
215         220         225

```

```

Ala Ile Ala Gly Ala Lys Leu Arg Arg Val Gln Arg Pro Glu Asp
      230      235      240
Ala Ser Gly Gly Ser Ser Pro Ser Gly Thr Ser Lys Ser Asp Ala
      245      250      255
Asn Arg Ala Ser Ser Gly Gly Gly Gly Gly Leu Met Glu Glu
      260      265      270
Met Asn Lys Leu Leu Ala Lys Arg Arg Lys Ala Ala Ser Gln Ser
      275      280      285
Asp Lys Pro Ala Glu Lys Lys Glu Asp Glu Ser Gln Met Glu Asp
      290      295      300
Pro Ser Thr Ser Pro Ser Pro Gly Thr Arg Ala Ala Ser Gln Pro
      305      310      315
Pro Asn Ser Ser Glu Ala Gly Arg Lys Pro Trp Glu Arg Ser Asn
      320      325      330
Ser Val Glu Lys Pro Val Ser Ser Ile Leu Ser Arg Met Lys Pro
      335      340      345
Ala Gly Ser Val Asn Asp Met Ala Leu Asp Ala Phe Asp Leu Asp
      350      355      360
Arg Met Lys Gln Glu Ile Leu Glu Glu Val Val Arg Glu Leu His
      365      370      375
Lys Val Lys Glu Glu Ile Ile Asp Ala Ile Arg Gln Glu Leu Ser
      380      385      390
Gly Ile Ser Thr Thr
      395

```

<210> 7

<211> 523

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2303465

<400> 7

```

Met Ala Ala Val Gly Arg Val Gly Ser Phe Gly Ser Ser Pro Pro
  1      5      10      15
Gly Leu Ser Ser Thr Tyr Thr Gly Gly Pro Leu Gly Asn Glu Ile
      20      25      30
Ala Ser Gly Asn Gly Gly Ala Ala Ala Gly Asp Asp Glu Asp Gly
      35      40      45
Gln Asn Leu Trp Ser Cys Ile Leu Ser Glu Val Ser Thr Arg Ser
      50      55      60
Arg Ser Lys Leu Pro Ala Gly Lys Asn Val Leu Leu Leu Gly Glu
      65      70      75
Asp Gly Ala Gly Lys Thr Ser Leu Ile Arg Lys Ile Gln Gly Ile
      80      85      90
Glu Glu Tyr Lys Lys Gly Arg Gly Leu Glu Tyr Leu Tyr Leu Asn
      95      100      105
Val His Asp Glu Asp Arg Asp Asp Gln Thr Arg Cys Asn Val Trp
      110      115      120
Ile Leu Asp Gly Asp Leu Tyr His Lys Gly Leu Leu Lys Phe Ser
      125      130      135
Leu Asp Ala Val Ser Leu Lys Asp Thr Leu Val Met Leu Val Val

```

140	145	150
Asp Met Ser Lys Pro Trp Thr Ala Leu Asp Ser Leu Gln Lys Trp		
155	160	165
Ala Ser Val Val Arg Glu His Val Asp Lys Leu Lys Ile Pro Pro		
170	175	180
Glu Glu Met Lys Gln Met Glu Gln Lys Leu Ile Arg Asp Phe Gln		
185	190	195
Glu Tyr Val Glu Pro Gly Glu Asp Phe Pro Ala Ser Pro Gln Arg		
200	205	210
Arg Asn Thr Ala Ser Gln Glu Asp Lys Asp Asp Ser Val Val Leu		
215	220	225
Pro Leu Gly Ala Asp Thr Leu Thr His Asn Leu Gly Ile Pro Val		
230	235	240
Leu Val Val Cys Thr Lys Cys Asp Ala Ile Ser Val Leu Glu Lys		
245	250	255
Glu His Asp Tyr Arg Asp Glu His Phe Asp Phe Ile Gln Ser His		
260	265	270
Ile Arg Lys Phe Cys Leu Gln Tyr Gly Ala Ala Leu Ile Tyr Thr		
275	280	285
Ser Val Lys Glu Asn Lys Asn Ile Asp Leu Val Tyr Lys Tyr Ile		
290	295	300
Val Gln Lys Leu Tyr Gly Phe Pro Tyr Lys Ile Pro Ala Val Val		
305	310	315
Val Glu Lys Asp Ala Val Phe Ile Pro Ala Gly Trp Asp Asn Asp		
320	325	330
Lys Lys Ile Gly Ile Leu His Glu Asn Phe Gln Thr Leu Lys Ala		
335	340	345
Glu Asp Asn Phe Glu Asp Ile Ile Thr Lys Pro Pro Val Arg Lys		
350	355	360
Phe Val His Glu Lys Glu Ile Met Ala Glu Asp Asp Gln Val Phe		
365	370	375
Leu Met Lys Leu Gln Ser Leu Leu Ala Lys Gln Pro Pro Thr Ala		
380	385	390
Ala Gly Arg Pro Val Asp Ala Ser Pro Arg Val Pro Gly Gly Ser		
395	400	405
Pro Arg Thr Pro Asn Arg Ser Val Ser Ser Asn Val Ala Ser Val		
410	415	420
Ser Pro Ile Pro Ala Gly Ser Lys Lys Ile Asp Pro Asn Met Lys		
425	430	435
Ala Gly Ala Thr Ser Glu Gly Val Leu Ala Asn Phe Phe Asn Ser		
440	445	450
Leu Leu Ser Lys Lys Thr Gly Ser Pro Gly Gly Pro Gly Val Ser		
455	460	465
Gly Gly Ser Pro Ala Gly Gly Ala Gly Gly Gly Ser Ser Gly Leu		
470	475	480
Pro Pro Ser Thr Lys Lys Ser Gly Gln Lys Pro Val Leu Asp Val		
485	490	495
His Ala Glu Leu Asp Arg Ile Thr Arg Lys Pro Val Thr Val Ser		
500	505	510
Pro Thr Thr Pro Thr Ser Pro Thr Glu Gly Glu Ala Ser		
515	520	

<210> 8
 <211> 348
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2363178

<400> 8
 Met Ala Lys Leu Leu Gln Pro Pro Pro Lys Phe Leu Pro Ser Glu
 1 5 10 15
 Trp His Ile Ala Asn Lys Asn Gln Tyr His Arg Ala Asp Ala Gln
 20 25 30
 Arg Ser Arg Ser Glu Arg Leu Val Ala Glu Ser Gln Arg Leu Val
 35 40 45
 Asp Glu Ile Glu Lys Thr Thr Arg Lys Ser Gln Ser Asp Val Asn
 50 55 60
 Lys Lys Leu Glu Gln Arg Leu Glu Glu Val Gln Phe Trp Lys Lys
 65 70 75
 Glu Leu Asp Asp Lys Leu Glu Gln Leu Val Asn Val Thr Asp Asp
 80 85 90
 Leu Leu Ile Tyr Lys Ile Arg Leu Glu Lys Ala Leu Glu Thr Leu
 95 100 105
 Lys Glu Pro Leu His Ile Thr Glu Thr Cys Leu Ala Tyr Arg Glu
 110 115 120
 Lys Arg Ile Gly Ile Asp Leu Val His Asp Thr Val Glu His Glu
 125 130 135
 Leu Ile Lys Glu Ala Glu Ile Ile Gln Gly Ile Met Ala Leu Leu
 140 145 150
 Thr Arg Thr Leu Glu Glu Ala Ser Glu Gln Ile Arg Met Asn Arg
 155 160 165
 Ser Ala Lys Tyr Asn Leu Glu Lys Asp Leu Lys Asp Lys Phe Val
 170 175 180
 Ala Leu Thr Ile Asp Asp Ile Cys Phe Ser Leu Asn Asn Asn Ser
 185 190 195
 Pro Asn Ile Arg Tyr Ser Glu Asn Ala Val Arg Ile Glu Pro Asn
 200 205 210
 Ser Val Ser Leu Glu Asp Trp Leu Asp Phe Ser Ser Thr Asn Val
 215 220 225
 Glu Lys Ala Asp Lys Gln Arg Asn Asn Ser Leu Met Leu Lys Ala
 230 235 240
 Leu Val Asp Arg Ile Leu Ser Gln Thr Ala Asn Asp Leu Arg Lys
 245 250 255
 Gln Cys Asp Val Val Asp Thr Ala Phe Lys Asn Gly Leu Lys Asp
 260 265 270
 Thr Lys Asp Ala Arg Asp Lys Leu Ala Asp His Leu Ala Lys Ile
 275 280 285
 Glu Gly Asn Phe Ser Pro Ser Ser Gly Arg Ala Glu Arg Ala Ala
 290 295 300
 Ser Gln Thr Ala Cys Pro Ala Gly Gly Asp Pro Gly Gln Arg Glu
 305 310 315
 His His Leu Tyr Arg Arg Ser Ala Val Tyr Ala Asp Glu Glu Ile
 320 325 330
 His Pro Thr Ser Gly Trp Gly Arg Pro Trp Gly Leu Gly Trp Gly

14/35

305	310	315
Pro Asp Ser Arg Phe Ala Ser Leu Gln	Pro Val Ser Asn Gln Ile	
320	325	330
Glu Arg Cys Asn Ser Leu Ala Phe Gly	Gly Tyr Leu Ser Glu Val	
335	340	345
Val Glu Glu Asn Thr Pro Pro Lys Met	Glu Lys Glu Gly Leu Glu	
350	355	360
Ile Met Ile Gly Lys Lys Lys Gly Ile	Gln Gly His Tyr Asn Ser	
365	370	375
Cys Tyr Leu Asp Ser Thr Leu Phe Cys	Leu Phe Ala Phe Ser Ser	
380	385	390
Val Leu Asp Thr Val Leu Leu Arg Pro	Lys Glu Lys Asn Asp Val	
395	400	405
Glu Tyr Tyr Ser Glu Thr Gln Glu Leu	Leu Arg Thr Glu Ile Val	
410	415	420
Asn Pro Leu Arg Ile Tyr Gly Tyr Val	Cys Ala Thr Lys Ile Met	
425	430	435
Lys Leu Arg Lys Ile Leu Glu Lys Val	Glu Ala Ala Ser Gly Phe	
440	445	450
Thr Ser Glu Glu Lys Asp Pro Glu Glu	Phe Leu Asn Ile Leu Phe	
455	460	465
His His Ile Leu Arg Val Glu Pro Leu	Leu Lys Ile Arg Ser Ala	
470	475	480
Gly Gln Lys Val Gln Asp Cys Tyr Phe	Tyr Gln Ile Phe Met Glu	
485	490	495
Lys Asn Glu Lys Val Gly Val Pro Thr	Ile Gln Gln Leu Leu Glu	
500	505	510
Trp Ser Phe Ile Asn Ser Asn Leu Lys	Phe Ala Glu Ala Pro Ser	
515	520	525
Cys Leu Ile Ile Gln Met Pro Arg Phe	Gly Lys Asp Phe Lys Leu	
530	535	540
Phe Lys Lys Ile Phe Pro Ser Leu Glu	Leu Asn Ile Thr Asp Leu	
545	550	555
Leu Glu Asp Thr Pro Arg Gln Cys Arg	Ile Cys Gly Gly Leu Ala	
560	565	570
Met Tyr Glu Cys Arg Glu Cys Tyr Asp	Asp Pro Asp Ile Ser Ala	
575	580	585
Gly Lys Ile Lys Gln Phe Cys Lys Thr	Cys Asn Thr Gln Val His	
590	595	600
Leu His Pro Lys Arg Leu Asn His Lys	Tyr Asn Pro Val Ser Leu	
605	610	615
Pro Lys Asp Leu Pro Asp Trp Asp Trp	Arg His Gly Cys Ile Pro	
620	625	630
Cys Gln Asn Met Glu Leu Phe Ala Val	Leu Cys Ile Glu Thr Ser	
635	640	645
His Tyr Val Ala Phe Val Lys Tyr Gly	Lys Asp Asp Ser Ala Trp	
650	655	660
Leu Phe Phe Asp Ser Met Ala Asp Arg	Asp Gly Gly Gln Asn Gly	
665	670	675
Phe Asn Ile Pro Gln Val Thr Pro Cys	Pro Glu Val Gly Glu Tyr	
680	685	690
Leu Lys Met Ser Leu Glu Asp Leu His	Ser Leu Asp Ser Arg Arg	
695	700	705
Ile Gln Gly Cys Ala Arg Arg Leu Leu	Cys Asp Ala Tyr Met Cys	
710	715	720

Met Tyr Gln Ser Pro Thr Met Ser Leu Tyr Lys
 725 730

<210> 10
 <211> 147
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2508327

<400> 10
 Met Pro Pro Pro Gln Lys Ile Pro Ser Val Arg Pro Phe Lys Gln
 1 5 10 15
 Arg Lys Ser Leu Ala Ile Arg Gln Glu Glu Val Ala Gly Ile Arg
 20 25 30
 Ala Lys Phe Pro Asn Lys Ile Pro Val Val Val Glu Arg Tyr Pro
 35 40 45
 Arg Glu Thr Phe Leu Pro Pro Leu Asp Lys Thr Lys Phe Leu Val
 50 55 60
 Pro Gln Glu Leu Thr Met Thr Gln Phe Leu Ser Ile Ile Arg Ser
 65 70 75
 Arg Met Val Leu Arg Ala Thr Glu Ala Phe Tyr Leu Leu Val Asn
 80 85 90
 Asn Lys Ser Leu Val Ser Met Ser Ala Thr Met Ala Glu Ile Tyr
 95 100 105
 Arg Asp Tyr Lys Asp Glu Asp Gly Phe Val Tyr Met Thr Tyr Ala
 110 115 120
 Ser Gln Glu Thr Phe Gly Cys Leu Glu Ser Ala Ala Pro Arg Asp
 125 130 135
 Gly Ser Ser Leu Glu Asp Arg Pro Cys Asn Pro Leu
 140 145

<210> 11
 <211> 57
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2524555

<400> 11
 Met Pro Asn Cys Arg Glu Ser Ser Phe Ser Ser Ala Thr Met Ser
 1 5 10 15
 Asp Lys Pro Asp Met Ala Glu Ile Glu Lys Phe Asp Lys Ser Lys
 20 25 30
 Leu Lys Lys Thr Glu Thr Gln Glu Lys Asn Pro Leu Pro Ser Lys
 35 40 45
 Glu Thr Ile Glu Gln Glu Lys Gln Ala Gly Glu Ser
 50 55

<210> 12
 <211> 452
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2900717

<400> 12
 Met Glu Val Thr Thr Arg Leu Thr Trp Asn Asp Glu Asn His Leu
 1 5 10 15
 Arg Lys Leu Leu Gly Asn Val Ser Leu Ser Leu Leu Tyr Lys Ser
 20 25 30
 Ser Val His Gly Gly Ser Ile Glu Asp Met Val Glu Arg Cys Ser
 35 40 45
 Arg Gln Gly Cys Thr Ile Thr Met Ala Tyr Ile Asp Tyr Asn Met
 50 55 60
 Ile Val Ala Phe Met Leu Gly Asn Tyr Ile Asn Leu Arg Glu Ser
 65 70 75
 Ser Thr Glu Pro Asn Asp Ser Leu Trp Phe Ser Leu Gln Lys Lys
 80 85 90
 Asn Asp Thr Thr Glu Ile Glu Thr Leu Leu Leu Asn Thr Ala Pro
 95 100 105
 Lys Ile Ile Asp Glu Gln Leu Val Cys Arg Leu Ser Lys Thr Asp
 110 115 120
 Ile Phe Ile Ile Cys Arg Asp Asn Lys Ile Tyr Leu Asp Lys Met
 125 130 135
 Ile Thr Arg Asn Leu Lys Leu Arg Phe Tyr Gly His Arg Gln Tyr
 140 145 150
 Leu Glu Cys Glu Val Phe Arg Val Glu Gly Ile Lys Asp Asn Leu
 155 160 165
 Asp Asp Ile Lys Arg Ile Ile Lys Ala Arg Glu His Arg Asn Arg
 170 175 180
 Leu Leu Ala Asp Ile Arg Asp Tyr Arg Pro Tyr Ala Asp Leu Val
 185 190 195
 Ser Glu Ile Arg Ile Leu Leu Val Gly Pro Val Gly Ser Gly Lys
 200 205 210
 Ser Ser Phe Phe Asn Ser Val Lys Ser Ile Phe His Gly His Val
 215 220 225
 Thr Gly Gln Ala Val Val Gly Ser Asp Thr Thr Ser Ile Thr Glu
 230 235 240
 Arg Tyr Arg Ile Tyr Ser Val Lys Asp Gly Lys Asn Gly Lys Ser
 245 250 255
 Leu Pro Phe Met Leu Cys Asp Thr Met Gly Leu Asp Gly Ala Glu
 260 265 270
 Gly Ala Gly Leu Cys Met Asp Asp Ile Pro His Ile Leu Lys Gly
 275 280 285
 Cys Met Pro Asp Arg Tyr Gln Phe Asn Ser Arg Lys Pro Ile Thr
 290 295 300
 Pro Glu His Ser Thr Phe Ile Thr Ser Pro Ser Leu Lys Asp Arg
 305 310 315
 Ile His Cys Val Ala Tyr Val Leu Asp Ile Asn Ser Ile Asp Asn
 320 325 330
 Leu Tyr Ser Lys Met Leu Ala Lys Val Lys Gln Val His Lys Glu

335	340	345
Val Leu Asn Cys Gly Ile Ala Tyr Val	Ala Leu Leu Thr Lys Val	
350	355	360
Asp Asp Cys Ser Glu Val Leu Gln Asp	Asn Phe Leu Asn Met Ser	
365	370	375
Arg Ser Met Thr Ser Gln Ser Arg Val	Met Asn Val His Lys Met	
380	385	390
Leu Gly Ile Pro Ile Ser Asn Ile Leu	Met Val Gly Asn Tyr Ala	
395	400	405
Ser Asp Leu Glu Leu Asp Pro Met Lys	Asp Ile Leu Ile Leu Ser	
410	415	420
Ala Leu Arg Gln Met Leu Arg Ala Ala	Asp Asp Phe Leu Glu Asp	
425	430	435
Leu Pro Leu Glu Glu Thr Gly Ala Ile	Glu Arg Ala Leu Gln Pro	
440	445	450
Cys Ile		

<210> 13
 <211> 281
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3088904

<400> 13

Met Asp Ala Ile Lys Lys Lys Met Gln Met Leu Lys Glu Asn Ala	
1 5 10 15	
Ile Asp Arg Ala Glu Gln Ala Glu Ala Asp Lys Lys Gln Ala Glu	
20 25 30	
Asp Arg Cys Lys Gln Leu Glu Glu Glu Gln Gln Ala Leu Gln Lys	
35 40 45	
Lys Leu Lys Gly Thr Glu Asp Glu Val Glu Lys Tyr Ser Glu Ser	
50 55 60	
Val Lys Glu Ala Gln Glu Lys Leu Glu Gln Ala Glu Lys Lys Ala	
65 70 75	
Thr Asp Ala Glu Ala Asp Val Ala Ser Leu Asn Arg Arg Ile Gln	
80 85 90	
Leu Val Glu Glu Glu Leu Asp Arg Ala Gln Glu Arg Leu Ala Thr	
95 100 105	
Ala Leu Gln Lys Leu Glu Glu Ala Glu Lys Ala Ala Asp Glu Ser	
110 115 120	
Glu Arg Gly Met Lys Val Ile Glu Asn Arg Ala Met Lys Asp Glu	
125 130 135	
Glu Lys Met Glu Leu Gln Glu Met Gln Leu Lys Glu Ala Lys His	
140 145 150	
Ile Ala Glu Asp Ser Asp Arg Lys Tyr Glu Glu Val Ala Arg Lys	
155 160 165	
Leu Val Ile Leu Glu Gly Glu Leu Glu Arg Ser Glu Glu Arg Ala	
170 175 180	
Glu Val Ala Glu Ser Arg Ala Arg Gln Leu Glu Glu Glu Leu Arg	
185 190 195	
Thr Met Asp Gln Ala Leu Lys Ser Leu Met Ala Ser Glu Glu Glu	

	200		205		210
Tyr Ser Thr Lys Glu Asp Lys Tyr Glu Glu Glu Ile Lys Leu Leu					
	215		220		225
Glu Glu Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu Phe Ala Glu					
	230		235		240
Arg Ser Val Ala Lys Leu Glu Lys Thr Ile Asp Asp Leu Glu Glu					
	245		250		255
Thr Leu Ala Ser Ala Lys Glu Glu Asn Val Glu Ile His Gln Thr					
	260		265		270
Leu Asp Gln Thr Leu Leu Glu Leu Asn Asn Leu					
	275		280		

<210> 14
 <211> 92
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3745193

<400> 14	
Met Asp Glu Gln Ile Arg Leu Met Asp Gln Asn Leu Lys Cys Leu	
1 5 10 15	
Ser Ala Ala Glu Glu Lys Tyr Ser Gln Lys Glu Asp Lys Cys Glu	
20 25 30	
Glu Glu Met Lys Ile Leu Thr Asp Asn Leu Lys Glu Ala Glu Thr	
35 40 45	
His Ala Glu Leu Ala Glu Arg Ser Val Ala Lys Leu Glu Lys Thr	
50 55 60	
Ile Asp Asp Leu Glu Asp Lys Leu Lys Cys Thr Lys Glu Glu His	
65 70 75	
Leu Cys Thr Gln Arg Met Leu Asp Gln Thr Leu Leu Asp Leu Asn	
80 85 90	
Glu Met	

<210> 15
 <211> 448
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3822123

<400> 15	
Met Arg Glu Cys Ile Ser Val His Val Gly Gln Ala Gly Val Gln	
1 5 10 15	
Ile Gly Asn Ala Cys Trp Glu Leu Phe Cys Leu Glu His Gly Ile	
20 25 30	
Gln Ala Asp Gly Thr Phe Asp Ala Gln Ala Ser Lys Ile Asn Asp	
35 40 45	
Asp Asp Ser Phe Thr Thr Phe Phe Ser Glu Thr Gly Asn Gly Lys	

50	55	60
His Val Pro Arg Ala Val Met Ile Asp Leu Glu Pro Thr Val Val		
65	70	75
Asp Glu Val Arg Ala Gly Thr Tyr Arg Gln Leu Phe His Pro Glu		
80	85	90
Gln Leu Ile Thr Gly Lys Glu Asp Ala Ala Asn Asn Tyr Ala Arg		
95	100	105
Gly His Tyr Thr Val Gly Lys Glu Ser Ile Asp Leu Val Leu Asp		
110	115	120
Arg Ile Arg Lys Leu Thr Asp Ala Cys Ser Gly Leu Gln Gly Phe		
125	130	135
Leu Ile Phe His Ser Phe Gly Gly Gly Thr Gly Ser Gly Phe Thr		
140	145	150
Ser Leu Leu Met Glu Arg Leu Ser Leu Asp Tyr Gly Lys Lys Ser		
155	160	165
Lys Leu Glu Phe Ser Ile Tyr Pro Ala Pro Gln Val Ser Thr Ala		
170	175	180
Val Val Glu Pro Tyr Asn Ser Tyr Leu Thr Thr His Thr Thr Leu		
185	190	195
Glu His Ser Asp Cys Ala Phe Met Val Asp Asn Glu Ala Ile Tyr		
200	205	210
Asp Ile Cys Arg Arg Asn Leu Asp Ile Glu Arg Pro Thr Tyr Thr		
215	220	225
Asn Leu Asn Arg Leu Ile Ser Gln Ile Val Ser Ser Ile Thr Ala		
230	235	240
Ser Leu Arg Phe Asp Gly Ala Leu Asn Val Asp Leu Thr Glu Phe		
245	250	255
Gln Thr Asn Leu Val Pro Tyr Pro Arg Ile His Phe Pro Leu Ala		
260	265	270
Thr Tyr Ala Pro Val Ile Ser Ala Glu Lys Ala Tyr His Glu Gln		
275	280	285
Leu Ser Val Ala Glu Ile Thr Asn Ala Cys Phe Glu Pro Ala Asn		
290	295	300
Gln Met Val Lys Cys Asp Pro Arg His Gly Lys Tyr Met Ala Cys		
305	310	315
Cys Leu Leu Tyr Arg Gly Asp Val Val Pro Lys Asp Val Asn Ala		
320	325	330
Ala Ile Ala Ala Ile Lys Thr Lys Arg Ser Ile Gln Phe Val Asp		
335	340	345
Trp Cys Pro Thr Gly Phe Lys Val Gly Ile Asn Tyr Gln Pro Pro		
350	355	360
Thr Val Val Pro Gly Gly Asp Leu Ala Lys Val Gln Arg Ala Val		
365	370	375
Cys Met Leu Ser Asn Thr Thr Ala Ile Ala Glu Ala Trp Ala Arg		
380	385	390
Leu Asp His Lys Phe Asp Leu Met Tyr Ala Lys Arg Ala Phe Val		
395	400	405
His Trp Tyr Val Gly Glu Gly Met Glu Glu Gly Glu Phe Ser Glu		
410	415	420
Ala Arg Glu Asp Met Ala Ala Leu Glu Lys Asp Tyr Glu Glu Val		
425	430	435
Gly Ile Asp Ser Tyr Glu Asp Glu Asp Glu Gly Glu Glu		
440	445	

<210> 16
 <211> 269
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 4217506

<400> 16
 Met Ser Asp Glu Glu Val Glu Gln Val Glu Glu Gln Tyr Glu Glu
 1 5 10 15
 Glu Glu Glu Ala His Glu Glu Ala Ala Glu Val His Glu Glu Val
 20 25 30
 His Glu Pro Glu Glu Val Gln Glu Asp Thr Ala Glu Glu Asp Ala
 35 40 45
 Glu Glu Glu Lys Pro Arg Pro Lys Leu Thr Ala Pro Lys Ile Pro
 50 55 60
 Glu Gly Glu Lys Val Asp Phe Asp Asp Ile Gln Lys Lys Arg Gln
 65 70 75
 Asn Lys Asp Leu Met Glu Leu Gln Ala Leu Ile Asp Ser His Phe
 80 85 90
 Glu Ala Arg Lys Lys Glu Glu Glu Glu Leu Val Ala Leu Lys Glu
 95 100 105
 Arg Ile Glu Lys Arg Arg Ala Glu Arg Ala Glu Gln Gln Arg Ile
 110 115 120
 Arg Ala Glu Lys Glu Arg Glu Arg Gln Asn Arg Leu Ala Glu Glu
 125 130 135
 Lys Ala Arg Arg Glu Glu Glu Asp Ala Lys Arg Arg Ala Glu Asp
 140 145 150
 Asp Leu Lys Lys Lys Lys Ala Leu Ser Ser Met Gly Ala Asn Tyr
 155 160 165
 Ser Ser Tyr Leu Ala Lys Ala Asp Gln Lys Arg Gly Lys Lys Gln
 170 175 180
 Thr Ala Arg Glu Met Lys Lys Lys Ile Leu Ala Glu Arg Arg Lys
 185 190 195
 Pro Leu Asn Ile Asp His Leu Gly Glu Asp Lys Leu Arg Asp Lys
 200 205 210
 Ala Lys Glu Leu Trp Glu Thr Leu His Gln Leu Glu Ile Asp Lys
 215 220 225
 Phe Glu Phe Gly Glu Lys Leu Lys Arg Gln Lys Tyr Asp Ile Thr
 230 235 240
 Thr Leu Arg Ser Arg Ile Asp Gln Ala Gln Lys His Ser Lys Lys
 245 250 255
 Ala Gly Thr Pro Ala Lys Gly Lys Val Gly Gly Arg Trp Lys
 260 265

<210> 17
 <211> 3620
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature

<223> Incyte ID No: 1285395

<400> 17

tgccggcgcc tgggactgaa gagggacggg tcccgcggcg agcgagctcc tgagcataag 60
ctgtggccat gactactgaa gtaggctctg tgtctgaagt gaagaaggac tctagccagt 120
taggaacaga tgcaaccaag gaaaaacctt aagaagtagc agaaaatcag cagaatcagt 180
cttccgatcc agaggaggaa aaaggttccc agccacctcc tgcagctgaa agccaaagta 240
gtctacgccg ccagaagaga gagaaggaaa catcggagag caggggtatt tctcggttca 300
taccgccatg gcttaagaag caaaagtcatt ataccttagt agtggccaaa gatggaggag 360
ataaaaaaga gcctacccaa gctgttgttg aagaacaggt cttagataaa gaggaacccc 420
ttccagaaga acagagacag gctaagggtg atgctgaaga aatggctcag aagaaacaag 480
agattaaagt tgaagtcaag gaagaaaaac cctcagttag caaggaagaa aaacctcag 540
tgagcaaagt ggagatgcag cctactgaat tagtaagtaa ggagagagaa gagaaggtaa 600
aagaaacaca ggaagacaaa ttagaaggag gagcagcaaa aagggagacc aaggaagtgc 660
agaccaatga gctgaaagca gagaaggcat ctcaaaaagt caccaagaag accaaaactg 720
tccagtgtaa agtgacctc ttagatggca ccgaatacag ctgtgacctg gagaacatg 780
ccaagggaca agtgttattt gacaaagtgt gtgaacacct caatctcttg gagaagact 840
actttggact tttgtttcag gaaagccctg agcagaaaaa ctgggttagat cctgctaaag 900
aaataaagag acaactgaga aaccttccat ggctattcac ttttaattgt aagttttatc 960
ctcctgatcc tttcgaattg actgaagata tcaccagata cttcttgtgc cttcagctcc 1020
ggcaggacat tgcctctggc cgcctgccct gctcttttgt gactcatgct ctcctgggat 1080
cctacacctt gcaggtgaa cttgggtgact atgacctcaga agaactggc agcatcgacc 1140
tcagtgaatt ccagtttgcc cctactcaga ctaaggagct ggaagagaag gtggcagagc 1200
tgcacaaaac ccacaggggc ttatcgccag cacaagctga tcccgagttc ttagaaaatg 1260
caaagaggct tccatgtat ggtgttgacc tacatcatgc caaggactca gaaggtgtg 1320
acatcaagct gggcgtgtgt gctaattggc tttcatttta caaagacaga ctgcgaatca 1380
atcgttttgc ttggccgaaa atcttaaaaa tttctataaa acgcagtaac tttctacatta 1440
aagtcagacc ggcagagctg gaacagtttg agagtaccat tggattcaaa ctgccaaacc 1500
accgggcagc gaaaagacta tggaaagtgt gcgtggagca tcatactttc tacaggcttg 1560
tttctccaga gcagccacca aaagccaagt tcttgacctt ggggtccaaa tttcgtata 1620
gtggccgcac ccaagcacag acccgccagg ccagcacctt catagatagg ccagcaccac 1680
actttgagc cacttctagt aaacgggtct ccaggagtct agatggagct ccgattgttg 1740
tcattggacca aagtcctatg aaggattttc ctggcgctgc tggggagatt tcagcctatg 1800
gacctggact tgtcagcatt gccgtggtac aagatgggga cggcaggagg gaagtggaa 1860
gcccaactaa agccccacat ttgcagctca ttgaaggaaa gaaaaattcc ttgagagtag 1920
aaggggataa tatttatgtc agacatagca atttaattgt ggaggaaactg gataaggccc 1980
aggaggacat actgaaacat caggctagca ttagtgaact caagcgcaat tttatggaat 2040
ccacacctga gccgcgcctt aatgaatggg aaaaacgacg tatcacacct ctgtccctac 2100
agacacaagg gatttcacat gagactctga atatagtggg ggagaagaag cgggcagagg 2160
ttgggaaaga cgaaagagta atcacagaag aaatgaatgg taaagagata tcacctggga 2220
gtggctcctg ggagattcgt aaggtggagc ctgtgacaca aaaagactcc acctccctgt 2280
cttctgagag cagcagcagc agcagtgaga gtgaggagga agacgtggga ggtaccgtc 2340
cccaccaccg agtgaccgag ggcaccatca gggagggaaca ggagtatgaa gaagagggtg 2400
aggaagaacc ccgcccggca gccaggttag tagagaggga ggaagcagtg ccggaagcca 2460
gccagtcac acaagcaggg gccagtgtaa tcacagtaga aacagtgatc caggaaaatg 2520
taggtgcccc aaagataccc ggagagaaga gtgtacacga aggcgctctt aagcaagaca 2580
tgggagaaga agcagaggaa gagccacaga aagttaacgg agagggtgtc catgttgaca 2640
ttgatgtttt gccacaaatt atttgttgtt cagagccacc agtggtaaaa acagagatgg 2700
taacaatttc tgatgcctca caaaggacag aaatctccac caaggaagtc cccattgtcc 2760
aaactgagac caaaacctc acatatgagt ctccacagat tgatggcggg gctgggtgtg 2820
attcgggcac gttactgacc gcacaaacca tcacatctga gtccgtgtca acaacgacaa 2880
ccacacacat caccaagact gtaaaagggt gaatttctga aacaagaatt gagaacgca 2940
ttgtgatcac aggagatgga gatattgatc atgaccaggc actggctcag gcgatcaggg 3000
aagccagaga gcagcacctt gacatgtcgg tcacaagagt ggtggtacac aaagaaacag 3060
agttggctga ggaaggggaa gattaagtaa gaaagtcatt ttttaacaa cactcaact 3120

tgtgaacccc tgaagatttt ttgaccgttc caagtcttaa tgccacacca ctattccagc 3180
gaattttatgc tacaactggg aacaatgacc agaagcctga agaattaaaa tgccaacacc 3240
aaacctttcc ttaccagctc tgggtctatat tgctcccatg catttaatat attattttgt 3300
tttataacca cttctaaata ttctcagttc ttcttttttg ttgttggttaa ttaaggggtt 3360
ttgggttttgt tttctgttta ctttgtgtgc aactacctgc ttttaatgac tcactttgat 3420
caaatgacag tgaacaaagc cagcccaagc tggtaagggtg ctgttcactt gaacagggtg 3480
tgttgcgagc aaaggaaact ctgtgactaa tttagatagt ggctttcctt cttctggatt 3540
cttttcattg aattctcaca gtaaatatctt acggagtttt caaattgcag caaatatact 3600
gtatgagaaa atattaatac 3620

<210> 18

<211> 4687

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1320252

<400> 18

cactccagct tgggtgacag agtgagaccg ggagagggag ccgcccgcagc cgccggcgct 60
gtggagatat tctctaagcc gctttcatca tgggagaaat agagcagagg ccgaccccag 120
gatcacgact gggggccccc gaaaattcgg ggatcagtag cttggaacgt ggacagaagc 180
cgcccccaac accttcagga aaactcgtgt ccatcaaaat ccagatgctg gatgacaccc 240
aggaggcatt tgaagttcca caaagagctc ctgggaagggt gctgctggat gcagtttgca 300
accacctcaa cctcgtggaa ggtgactatt ttggcctcga gtttcctgat cacaaaaaga 360
tcacggtgtg gctggatctc ctaaaaccca ttgtgaaaca gattagaagg ccaaagcacg 420
ttgttggttaa gtttgtgtg aaattctttc cgcctgacca cacacaactc caagaagaac 480
tcacaaggta cctgttcgct ctgcagggtga agcaggactt ggctcaaggc aggttgacgt 540
gtaatgacac cagcgcagct ctcttgattt cacacattgt gcaatctgag attggggatt 600
ttgatgaagc cttggacaga gagcacttag caaaaaataa atacatacct cagcaagacg 660
cactagagga caaaatcgtg gaatttcacc ataaccacat tggacaaaaca ccagcagaat 720
cagatttcca gctcctagag attgcccgtc ggctagagat gtatggaatc cggttgcacc 780
cggccaagga cagggaaagg acgaagatca atctggccgt tgccaacacg ggaattctag 840
tgtttcaggg ttctactaag atcaatgcct tcaactgggc caagggtgcg aagctgagct 900
tcaagaggaa gcgctttttc atcaagctcc ggccagatgc caatagtgcg taccaggata 960
ccttgggaatt cctgatggcc agtcgggatt tctgcaagtc cttctggaaa atctgtgttg 1020
aacatcatgc cttctttaga ctttttgaag agcccaaacc aaagcccaag cccgtcctct 1080
ttagccgggg gtcatcatct cggttcagtg gtcggactca gaagcagggt ctcgactatg 1140
ttaaagaagg aggacataag aagggtgcagt ttgaaaggaa gcacagcaag attcattcta 1200
tccggagcct tgcttcacag cctacagaac tgaattcgga agtgctggag cagtctcagc 1260
agagcaccag ccttacattt ggagaagggt ccgaatctcc agggggccag agctgccggc 1320
gaggaaagga accgaagggt tccgccgggg agccgggggc gcacccgagc cctgcgccga 1380
ggagaagccc cgcggttaac aagcaggcgg acggagccgc ctgcggcggc acggaggaag 1440
aggaggagggt cgtaaggat agggaccagc agagttaaacc tcagcccccg cagccaagca 1500
caggctccct gactggcagt cctcaccttt ccgagctgtc tgtgaactcg cagggggggag 1560
tgccccctgc caacgtgacc ttgtctccca acctgagccc cgacaccaag caggcctctc 1620
ccttgatcag cccgctgctg aatgaccagg cctgcccccg gacggacgat gaggatgagg 1680
gccggaggaa gagattccca actgataaag cgtacttcat agctaaggaa gtgtctacca 1740
ccgagcgaac atatctgaag gatctcgaag ttatcacttc gtggtttcag agcacagtga 1800
gcaaagagga cgccatgccg gaagcactga aaagtctcat attcccgaat ttgaaacctt 1860
tgcacaaaatt tcatactaatt ttctcaagg aaattgagca acgacttgcc ctgtgggaag 1920
gccgctcaaa tgcccaaatc agagattacc aaagaatcgg cgatgtcatg ctgaagaaca 1980
ttcagggcac gaagcacctg gcggctcacc tgtggaagca cagcgaggcc ttggaggccc 2040

tggagaatgg aatcaagagc tcccggcggc tggagaactt ctgcagagac tttgagctgc 2100
 agaagggtgtg ttacctaccg ctcaacacct tectctctgcg gccactgcac cggctcatgc 2160
 actacaagca ggtcctggag cggctgtgca aacaccaccc gccagagccac gccgacttca 2220
 gggactgccc agccgctttg gcagagatca cggagatggg ggcacagctc cagcgtacga 2280
 tgatcaagat ggagaatttc cagaagctgc acgaactcaa gaaagatttg attggcattg 2340
 acaatcttgt ggttccggga agggagttca tccgtctggg cagcctcagc aagctctcgg 2400
 ggaagggggct ccagcagcgc atgttcttcc tgttcaacga cgtcctgcta tacacgagcc 2460
 gggggctgac ggcctccaat cagtttaaaag tccacgggca gctcccgcctc tatggcatga 2520
 cgattgagga gagcgaagac gagggggggg tggccactg cctgaccctc cggggccagc 2580
 ggcagtccat catcgtggcc gccagttctc ggtccgagat ggagaagtgg gttgaggaca 2640
 tccagatggc cattgacctg gcggagaaga gcagcagccc cggccctgag ttcctggcca 2700
 gcagcccccc tgacaacaag tcccctgatg aagccaccgc ggctgaccag gagtccagag 2760
 atgacctgag cgcctcgcgc acatcgtgg agcgccaggc cccgcaccgc ggcaacacaa 2820
 tgggtgcacgt gtgctggcac cgcaacacca gcgtctccat ggtggacttc agcatcgag 2880
 tgagaatca gttgtctgga aacctctgca ggaaattcaa aaacagcaac ggggtggcaga 2940
 agctgtgggt ggtgttcaca aacttctgce tgttcttcta caaatcacac caggacaatc 3000
 atccccttgc cagcctgcct ctgctcggct actcgtcac catcccctc gagtccgaga 3060
 acatccagaa agactacgtg ttcaagetgc acttcaagtc ccacgtctac tacttcaggg 3120
 cggaaagcga gtacacgttc gaaaggtgga tggaaagtga ccgcagtgc accagctctg 3180
 cctcgcgacc ccacgtgttg agtcacaaag agtctcttgt gtattgatgg ccggacacac 3240
 tctgttccgc agtggctgct ttcctggaag acgtttcctt tcttctgtat taatgaagcc 3300
 tggtaaaatt aacacctgtc tgaatatcaa aaacatggct tcccagcagc tctcctgtct 3360
 ccacagccgc gttttttaac cccgacctct cagcgtctga atgaacagcg ctcccacctc 3420
 cagtcctggc atccgctggg ggcgtgttcc tttagctagt gccagtatta aaacattgtc 3480
 attacgagag tgccaaatga catcttccct ccacctgccc cctgaaaaac agtacacaca 3540
 catccgttca acacaagaca gggcaagtgt ttttcttcc aaaaaaagt ctttcttcta 3600
 ttattttcac ctattggctg ctgcatttta cgaagtggac ttcccgggtg ttgtttgttt 3660
 gtttgcaata cactcagtgc agccttaagc aaatgagatc attttcagat ttcatTTTTT 3720
 ttttcagttc ttctactttt gtaataatag gaagttagta ggactcactt ctctgattaa 3780
 taagcaattt gcagcacaca gcgttccact gcgggggttcc acgctcacct gaaaacacct 3840
 gttcccaacc tacttcttgg tgcaagttga ccaaactcgt ttaagtggta actctttcca 3900
 accgtagcag ggttgttttc tgtaaagcaa agccgagatc cagtgcataa cctggactgt 3960
 caccgtcctg tgagtgggtg acacaatggg aagataataa gccgtgggtg ttgtctgtct 4020
 gtctgtgtca caagcatgaa aacccgtgtg tcattgatca gcaccatttg tggatgttc 4080
 cctgatgagc gtttagtgag cctgctggct gcagagcact atgaaatcat ggtacgtagt 4140
 cccgggcacc tgcgttatt cctatatcct cctgcaactg tggtttga aa ctgcgcatc 4200
 tctagtagta tatatcgtgc ctgtcttcaa aaacatttcc ctttttatac tcattcccc 4260
 caggcatggg gtatgtctag tccgactgca cagggaacac gggttccagt ggctttggcc 4320
 cctactcggg aaacgtctgc ctgttctcga tggatgagg gtggtctgcca ttccttgggt 4380
 tttcttaagc cttttctaac gagagtctca aacaagcggg ggcgagggcc aattcaacc 4440
 cattctttcc agcgcgccgc accatagcac ctgcccacct gagaaccagg aacgcacct 4500
 ctctgtggag ctctgactgg tgtacctgga aacaaacagc aacttgcaaa cggacgaaga 4560
 gectgccgtg tgttaatcat ttgccttaca agatgtacca gacgggttcc agtactaaca 4620
 aagggataaa aaatacctca cgcacaatc cagcatattg atgttttaag gcaaaacaaa 4680
 aaaaaaa

4687

<210> 19
 <211> 2331
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1259001

<400> 19

```
gggaaatact ggggttgagg cagggtgact ggggggggaa tctcagaggt gtggatgtgt 60
tttcaggcac ctgaagaact cgtcttgcat ttggctgtca aagtcgcca ccaggcttcc 120
ctgcctctgg tggatttcat catccagaac ggtggtcacc tggatgcca ggctgctgac 180
gggaacacgg ctctgcacta cgcagcactc tacaaccagc ccgactgcct caagctgctg 240
ctgaagggga gagctttggt tggcacagta aatgaagcag gcgagacagc tctggacata 300
gccaggaaga agcaccacaa ggagtgtgag gagctgctgg agcaggccca ggcggggacc 360
tttgccttcc ctctacatgt ggactactcc tgggtaattt ccacagagcc tggctctgac 420
agtgaaggagg atgaggaaga gaagcgtgc ttgctgaagc tcccggccca ggctcactgg 480
gccagtggga ggtgggacat cagcaacaag acctatgaga ctgtcgccag cctggggagca 540
gccacccctc agggcgagag tgaggactgt ccccgccctc tgccagtcaa aaactcttct 600
cggactttgg tccaagggtg tgcaagacat gccagtggag atcgttctga agtctccagc 660
ctgagtccag agggccctga gacccctgag agcctgggca gtccagcctc ctctccagc 720
ctgatgagcc ccttggaaac tggggatccc agccaagccc caccacactc tgaagagggc 780
ctccgagagc ccccaggcac ctccagaccc agcctgacat cggggaccac cccttcggag 840
atgtacctcc ccgtcagatt cagctccgag agcactcgct cctatcgggg gggggcgcg 900
agccctgaag atggteccct agccaggcag cctctgcca gaaggaaact gcccgttggc 960
atcactgaag gagatggctc aaggactggg agtctccag caagtctgtg gcaacttttg 1020
caagactagc tccttgctgg cccccacatg ccccatgcta ggccccaatg ttcagagctg 1080
ggacttgagc tcacaaaact ggggagctga gacatttgtt ctcttgagtc tcaactcttc 1140
tgtcccttgg gctctgttag ctggccttct tcctgcca ca ggcctatgct ctaccaagga 1200
cacatggcct ttccctgtta gggctgatgg cgggtcttct ctatctcatt acccgctagg 1260
ggcctgggag cctctgtggc ggatctgagt gctcctgagc tggcttcagc tgcagaactc 1320
tcagtccttc atcagatcga gactctatct ccccgctcag tctgggggct tcacaagggc 1380
aggagagccc tccatcactg acttccagat cagggaccct gccaaagtagg gactgtcttc 1440
tcagccagcc atttattagt ctaatatctc tcaactaaat tccaactcta tgtctggacc 1500
tgtgttaggc acttcagata ccacacgagt aagacaaggg ccctgcaggg gtggctcctt 1560
ggtggaaagc tggctttaag ggttgggctt ggggaataggc agggtcagat tccagggcac 1620
ggctctggac tcagctggtt tatacctata tgaccattac agttgtctac agatcacatc 1680
cattctggct ggtcaacatg catgctgtac tggctgttaa ataaaaatat tctgaatgtc 1740
actccttttg agggacagca cagccttccc taggcattct cctatattcc ccagccaaat 1800
tgtagagtca gatgcaccca catttgcttg tgccttgat ttagcaggaa ggaaaggaa 1860
agtgggggtt gatggatgcc cactctctct ctcttctct tggccaactc aggagcctt 1920
tagtctgagg gaatggagag gcaaagaaag aaggagagat aatagaattg ggagggcaga 1980
gacttaaggg ttctgcttcc cagccctaga aattctatca ttgctcagcc ccaatgagaa 2040
agcagataca cctaagccat catcaaccac taacatctca acttgccagt tgcctgggtg 2100
tgggcccctg caggaatggg ccaagccaag caggggagac tagagagcac caatggccaa 2160
cacagctgcc tggctgggga ggctgtgctg ttccccctgg agacctgact ggtctgtggt 2220
tcccacagga acagggttgt cttttgagcc cccagtgtct ggtttcattc atctcagact 2280
tgttatttca ctcatctcta ataaaggatt ggggggtcaa aaaaaaaaaa a 2331
```

<210> 20

<211> 1918

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1627027

<400> 20

```
cagtggccct gggaccagct ctgctccttg caccgcgctc cctgcctgga cacaggetca 60
ctcgctgcct tcttctgggg gaaaccagct tcttgccagc cacagctgct gcctccgcca 120
ctggccaccg cccctgtcct gggagtcctt tggccagac acccacctga cttagtggct 180
```

```

cctctgcagg aaaggtggct gccccctgcg ttcctccatc caaccatgag ctggtgccc 240
tcaccactga gaatgcacca aagaatgtag tggacaaggg agaaggagcc tcccggggtg 300
gaaacacacg gaaaagcctc gaggacaacg gctccaccag ggtcaccctg agtggtccagc 360
cccacctcca gcccacaga aacatgagtg tgagccggac catggaggac agctgtgagc 420
tggacctggg gtacgtcaca gagaggatca tgcgtgtctc cttccccagc acagccaatg 480
aggagaactt ccggagcaac ctccgtgagg tggcgagat gctcaagtcc aaacatggag 540
gcaactacct gctgttcaac ctctctgagc ggagacctga catcacgaag ctccatgcca 600
agggtactgga atttggctgg cccgacctcc acacccagc cctggagaag atctgcagca 660
tctgtaaggc catggacaca tggctcaatg cagacctca caatgtcgtt gttctacaca 720
acaagggaac ccgaggcagg ataggagttg tcatcgcggc ttacatgcac tacagcaaca 780
tttctgccag tgcggaccag gctctggacc ggtttgcaat gaagcgggtc tatgaggata 840
agattgtgcc cattggccag ccatcccaaa gaaggtagct gcattacttc agtggcctgc 900
tctccggtc catcaaaatg aacaacaagc ccttgtttct gcaccacgtg atcatgcacg 960
gcatcccaa cttttagtgt aaaggaggat gtcggccatt tctccgcac taccaggcca 1020
tgcaacctgt gtacacatct ggcacttaca acatccagg agacagccag actagcgtct 1080
gcatcaccat cgagccagga ctgctcttga agggagacat cttgtgaag tgctaccaca 1140
agaagtccg aagccagcc cgagacgtca tcttccgtgt gcagttccac acctgtgcca 1200
tccatgacct gggggttgtc tttgggaagg aggaccttga tgatgtttc aaagatgatc 1260
gatttccaga gtatggcaaa gtggagtttg tattttctta tgggcccagag aaaattcaag 1320
gcatggagca cctggagaac gggccgagcg tgtctgtgga ctataacacc tccgaccccc 1380
tcatccgctg ggactcctac gacaacttca gtgggcatcg agatgacggc atggaggatg 1440
ggaacaaaca gaataccaat agccagtcaa ttggaagcat ctgaggtggc ctggaggatc 1500
aatatactg gccagacaca cactggcctt cccaaagtta ggcctccaa aatgtcaagt 1560
tgccaagcca gaatccaaag ctttgcactg agaacttcat gttggggctc ctgtccctc 1620
ctggagccct gcctgggtga caccacagtc cttctattca ggtcctgtgt tcacctctgg 1680
gaagtgcagg accctgtggg gttttttctt ttctctttc caagccaagg aagtgtctc 1740
gctcctggag tctgcctgtg ggaggggaaa gggggagaga gagggaaaaa aagatttcca 1800
ccttattgtt cagcagctgg aaaattgtt tcatctgttc tgccttccat ttgctgagaa 1860
tggaaaaaaa atgtggaaaa tttggggaaa taaatctcaa taccctcaaa aaaaaaaa 1918

```

<210> 21

<211> 1386

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1905315

<400> 21

```

cggcgggctc cacacgcgct ggcgccgccc cgggcccac gcgcggccca tgtcctccgc 60
gccgcgctcg cccaccccgc ggcccgcag gatgaagaag gacgagtcgt tcttgggcaa 120
gctggggcggc accctggcca ggaagcggag ggcgcgcgag gtgagtgacc tgcaggaaga 180
aggcaagaat gccatcaact caccgatgtc ccccgccctg gcggatgttc accctgaaga 240
caccagctc gaggagaacg aggagcgac gatgattgac cccacttcca aggaagaccc 300
caagtccaag gaactggtca aggtcctcct cgactggatt aatgacgtgc tgggtggagga 360
gaggatcatt gtgaagcagc tggaggaaga cctgtatgac ggccaggtgc tgcagaagct 420
cttggaaaaa ctggcagggt gcaagctgaa tgtggtgag gtgacacagt ccgaaatagg 480
gcagaaaacag aagctgcaga cgggtgctgga agcagtacat gacctgtgc gggcccgagg 540
ctgggcgctc cgggtggagc tggactcaat tcacgggaag aacctggtgg ccatcctcca 600
cctgctggte tctctggcca tgcacttcag gggcccccac cgccttctg agcatgtaac 660
ggtgcagggt gtggtcgtgc ggaacgggga aggcctgctg cattccagcc acatctcgga 720
ggagctgacc acaactacag agatgatgat gggcggttc gagcgggatg ctttcgacac 780
gctgttcgac cagcggcccg ataagctcag cgtggtgaag aagtctctca tcacttttgt 840

```

gaacaagcac ctgaacaagc tgaatttggg ggtgacggaa ctggagaccc agtttgcaga 900
tggcggtgtac ctggttctgc tcatgggcct tctggaagac tactttgttc ctctccacca 960
cttctacctg actccggaaa gcttcgatca gaaggteccac aatgtgtcct tcgcctttga 1020
gctgatgctg gacggaggcc tcaagaaacc caaggctcgt cctgaagacg tgggttaactt 1080
ggacctcaaa tccacctga gggttcttta caacctgttc accaagtaca agaacgtgga 1140
gtgacggggg agctgtggat ggtggcagga gtgtccagc aagaaaggcg gcacccgtct 1200
gtgccctgtg cctttccagg gagccaggcg ccatgggctt ctggtccaag ctgtgttgac 1260
tgtcatcccc accccacccc tacctcacgc ctgccccacc ccctgcctct tttggttgtt 1320
gttcttaatc tcctctccat gtagttccca gtgggcaaga gcctttgaaa atgcaggatt 1380
ctaaaaa 1386

<210> 22

<211> 1745

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1997789

<400> 22

ccgggtcgcc cctggcccgg cgcgcccgtc cccggcagcg acaatgagtg aacagagtat 60
ctgccaaagcc cgggcttccg tgatggtcta cgatgacacc agtaagaaat ggggtaccaat 120
caaacctggc cagcagggat tcagccggat caacatctac cacaacactg ccagcaacac 180
cttcagagtc gttggagtca agttgcagga tcagcagggt gtgatcaatt attcaatcgt 240
gaaagggctg aagtacaatc aggccacgcc aaccttccac cagtggcgag atgcccgcga 300
ggctctacggc ttaaaactttg caagtaaaga agaggcaacc acgttctcca atgcaatgct 360
gtttgccctg aacatcatga attccaaga aggaggcccc tccagccagc gtcagggtgca 420
gaatggcccc tctcctgatg agatggacat ccagagaaga caagtgatgg agcagacca 480
gcagcagcgt caggaatctc tagaaagaag aacctcggcc acagggccca tcctccacc 540
aggacatcct tcatctgcag ccagcgcccc cgtctcatgt agtgggcctc caccgcccc 600
cccaccteta gtcccacctc caccactgg ggctacccca cctccccac cccactgcc 660
agccggagga gcccaggggt ccagccacga cgagagctcc atgtcaggac tggccgctgc 720
catagctggg gccaaagctga gaagagtcca acggccagaa gacgcatctg gaggctccag 780
tcccagtggt acctcaaagt ccgatgccaa ccgggcaagc agcgggggtg gcggaggagg 840
cctcatggag gaaatgaaca aactgctggc caagaggaga aaagcagcct cccagtccga 900
caagccagcc gagaagaagg aagatgaaag ccaaattgga gatcctagta cctccccctc 960
tccggggacc cgagcagcca gccagccacc taactcctca gaggctggcc ggaagccctg 1020
ggagcggagc aactcgggtg agaagcctgt gtccctgatt ctgtccagga tgaagcctgc 1080
tgggagcgtg aatgacatgg ccctggatgc cttcgacttg gaccggatga agcaggagat 1140
cctagaggag gtggtgagag agctccacaa ggtgaaggag gagatcatcg acgccatcag 1200
gcaggagctg agtgggatca gcaccacgta aggggcccgc ctcgctgcgc tgattcgtcg 1260
agcccatccg gcgacagagg acagccagaa gccagccag cccagactc cagtgcacca 1320
gagcacgcac aggagcctgg gcgcgctgct gtgaaacgtc ctgacctgtg atcacacatg 1380
acagtgagga aaccaagtgc aactcctggg tttttttaga ttctgcctga caccgaacac 1440
caggctctgct cgtctttttt gtgttttata tttgcttatt taaggtagat ttctttgggt 1500
ttctagagac gcccctaagt cacctgcttc attagacggg ttccagggtt tctcccagg 1560
gacgctgtta gcgcctcagc tggcggtgac agccggccca gcgtggcgcc accacacacc 1620
gcagagctgt ccaggcacag ctccgtcccc agcgtcatg gtgttgaaac tgtctgtcat 1680
gcaccacggg gtctgtgtcc acacagtaat aaacggttta ctgtccgcaa aaaaaaaaaa 1740
aaagg 1745

<210> 23
<211> 2451
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2303465

<400> 23
cgctcagcc gcctcgaca tttagtcttg ccgggagtg tgtgattccc gaccaagatg 60
gcggccgtgg ggcgagtcgg ctctctcggg tcttctccgc cgggattatc ctcgacttac 120
actggcgggc ccttgggcaa cgagatagcg tcgggcaacg gtggcgccgc ggcaggcgac 180
gacgaggacg ggcagaacct ttggtcctgc atcctcagcg aggtctccac ccgctcgcgc 240
tccaagctcc ctgcggggaa gaacgtgcta ctgctgggtg aagatggagc tggaaaaaca 300
agcttaataa gaaaaattca ggaatagag gagtataaga aaggaagagg attggaatat 360
ttgtacttaa atgtgcatga tgaagacagg gatgatcaaa caagatgtaa tgtttggatc 420
ttagatggag acctatatca caaaggcctc cttaaatttt cactggatgc cgtatctctg 480
aaggatactc tagttatgct ggttgttgac atgtcaaaagc cttggactgc tttggattct 540
ttacagaaat gggcaagtgt tgttagagaa catgttgaca aactgaaaat ccctcctgaa 600
gaaatgaaac aaatggaaca aaagtgtatt agagacttcc aagaatatgt agagccagga 660
gaagacttcc cggcttctcc ccagagaaga aatactgcgt cacaagaaga caaagatgac 720
agtgtagttt tacctctggg tgcggataca cttacacata acttgggcat tccagtacta 780
gtagttttga caaagtgtga tgccattagt gtattggaga aagaacatga ctacagagat 840
gaacattttg attttattca gtcacatata cggaagtttt gtttacagta tgggtgcagca 900
cttattttaca cttcagtaaa agaaaacaaa aatatagact tagtatataa atacatcgtt 960
cagaaactat atggatttcc ctataagatt cctgctgttg ttgtggaaaa ggtatgcagta 1020
ttatttcag caggggtggga taatgataag aaaataggaa tattacatga aaattttcaa 1080
acattaaaag cagaagataa tttgaagac atcataacta aaccacctgt tcgaaagttt 1140
gtacatgaga aggaatttat ggcagaagat gatcagggtg ttcttatgaa gctacagtcc 1200
cttttagcaa agcaaccacc aactgcagct ggaaggcctg tggatgcctc accaagagtc 1260
ccaggaggct cccacgaaac accaaataga tctgtatcat ctaatgttgc cagcgtgtca 1320
cccattcctg ctgggtcaaa aaaaattgat ccaaactga aagctggagc tacaagtga 1380
ggcgttcttg caaatttctt caacagtttg ttgagtaaaa agactggctc tccaggaggc 1440
cctggtgtga gtggtgtag ccctgcaggt ggggctggag gtggaagcag tggtttacc 1500
ccatccacca aaaagtcagg ccagaagcct gtcttagatg ttcatgcaga actagacaga 1560
attacacgaa aaccagttac agtttctccc acaacacctc catctctac ggaaggagaa 1620
gcttcttgaa gataccaaat aaagccattt attctgtttt ctgggataat gtaaacatgc 1680
ctctgccttt tcttcaaaa gtggaattag aaagctggag tgcttcttca gatggactaa 1740
atztatgtcg tgtgtgtgtg tgtgtgtgtg tgtggttacc cattttttag aaggagccgt 1800
acagaagaaa aattattcta cattatgtag gattgctgtt tgcattgcca ttttgcataa 1860
gaaagtaatt tttgattttg aaaatctcaa aacttttaga tctgaaatac agccatgtga 1920
tcgatcatat tctaaaggct atttaaaaca tgtaaaagga tttggggaac ggcagaaaac 1980
atgcagtttg ggcatttgac tgacttggaa gtctaagctt attttagtta taactattaa 2040
aatcattttt aaaaatttgt tagttttgct gacagagaaa aatcgtcagt tgtcagattt 2100
tgcacaccac aataaatgta ccaccacaca cggaaatagc taagaaaact atcagatagc 2160
gtttgatata ctagtcatg tctcaatcac tgatcctgta agttgtcatc aaaatatgat 2220
ttagaaatat tggccaaggt gttgctttta ctgaggagaa aagaaagcac actgcctaaa 2280
tgtgtaaaag aaaaatgcag aggttattaa aatgtaaaaga agtaacaatc tttggatttg 2340
tctatacata tatatatata tatatggctt tgccttaata taccctctt tttgtttgtg 2400
actttcaact gtaatcagtt aataaagtat ttattctctg caaaaaaaaa a 2451

<210> 24
<211> 1162

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2363178

<400> 24
ggaggctccc atcccagct tgcgtagtgg ttctgtgtgg cgctgaggaa tttggaacc 60
tcaaatggct aaactattac aacctccgcc caagttcctg cctcagagt ggcacattgc 120
taacaagaac cagtaccaca gagcagacgc tcaaaggctc cgatcagaac gcctggtcgc 180
agaaagccag aggcttgtgg atgaaattga aaagaccaca agaaaatctc aaagcgatgt 240
gaacaagaaa ctagaacaga gactcgagga agtccagttc tggagaagg agttagatga 300
caaacttgag cagcttgtga atgtaactga tgatctactc atatataaga tcagattgga 360
aaaagccctg gagaccttga aagagccctt gcacatcact gagacatgcc tggcatacag 420
ggagaagcgc attggcattg acctgggtgca cgacacagtg gagcatgagc tgataaaggga 480
ggctgagatc atccagggca ttatggctct gctgaccctg acctggagg aggcttccga 540
gcagattcgg atgaaccgct ctgccaagta caatcttgag aaggatttga aggacaagtt 600
tgtggccctg accatagatg atatctgctt ctgcctcaac aacaactcac caaacatcag 660
atattctgag aacgccgtga ggattgagcc aaactccgtg agtctggaag actggttgga 720
cttctccagc accaatgtgg agaaggtga caagcagcgg aacaactccc tgatgctgaa 780
agccctggtg gatcgaatcc tgtcccagac agccaatgat ctgcgcaagc agtgtgatgt 840
ggtggacacg gcattcaaga atgggctgaa ggatacaaaag gatgccaggg acaagctggc 900
tgatcatctg gccaaagattg aagggaaactt tagcccaagc tcaggcagag ctgaaagggc 960
tgcacgcag acagcttgcc ctgcaggagg agatccaggt caaagagaac accatttata 1020
tcgacgaagt gctgtgtatg cagatgagga aatccatccc acttcgggat ggggaagacc 1080
atggggctctg ggctgggggc ctccgccctg atgctgtctg ctaatagtag ggctagttcc 1140
aattctcatt aaaccgggat ga 1162

<210> 25
<211> 4527
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2363327

<400> 25
agcccgggac gcgggctggg gagccggggc gaggggagac gccccgcgc cagagtttcc 60
ccctttctag ggtgaggatg gttctacaca gccacccgga gttccttagt tgaaagggtgc 120
gccctgctgt gacagcatgg acaccacgtt gctgaaaaca tgctttggga ctgccactga 180
atztatcttt tgcgggttta tgacaaagtt attagtagtt tccctttttt gaattagtat 240
tttgaagtta atatcacaat gagtttccag gcttatggag ccaagaaaaa gtcacttcac 300
cctactggga agagcggatt ttttacttgc ttcttcaaga atgcagcgtt acagacaaac 360
aaacacaaaa gctccttaaa gtaccgaagg aagtatagga cagtatatc aagatcgttc 420
tgtggggcat tcaaggattc ctcttgcaaa aggcaagaaa aatcagattg gattaaaaat 480
tctagagcaa cctcatgcag ttctctttgt tgatgaaaag gatgttgtag agataaatga 540
aaagtccaca gagttacttt tggcaattac caattgtgag gagaggttca gcctgtttta 600
aaacagaaac agactaagta aaggcctcca aatagacgtg ggctgtcctg tgaaagtaca 660
gctgagatct ggggaagaaa aatttccttg agttgtacgc ttcagaggac ccctgttagc 720
agagaggaca gtctccggaa tattcttttg agttgaattg ctggaagaag gtcgtggtca 780
aggtttcact gcggggtgt accaaggga acagcttttt cagtgtgatg aagattgtgg 840
cgtgtttgtt gcattggaca agctagaact catagaagat gatgacactg cattggaaa 900

tgattacgca ggtcctgggg acacaatgca ggtcgaactt cctccttttg aaataaactc 960
 cagagtttct ttgaaggttg gagaaacaat agaactctgga acagttatat tctgtgatgt 1020
 ttggccagga aaagaaagct taggatattt tgttggtgtg gacatggata accctatttg 1080
 caactgggat ggaagatttg atggagtgcg gctttgtagt ttgctgtgtg ttgaaagtac 1140
 aattctattg cacatcaatg atatcatccc agagagtgtg acgcaggaaa ggaggcctcc 1200
 caaacttgcc tttatgtcaa gaggtgttgg ggacaaaggt tcatccagtc ataataaacc 1260
 aaaggctaca ggatctacct cagaccctgg aaatagaaac agatctgaat tttttatata 1320
 cttaaatggg tcttctgttg actcacaacc acaatccaaa tcaaaaaata catggtacat 1380
 tgatgaagtt gcagaagacc ctgcaaaatc tcttacagag atatctacag actttgaccg 1440
 ttcttcacca ccactccagc ctctcctgtg gaactcactg accaccgaga acagattcca 1500
 ctctttacca ttcatgtcca ccaagatgcc caataccaat ggaagtattg gccacagtc 1560
 actttctctg tcagccagct ctgtaattga agagctaaac actgcaccg tccaagagag 1620
 tccacccttg gccatgcctc ctgggaactc acatgggtcta gaagtgggct cattggctga 1680
 agttaaggag aacctctctt tctatggggt aatccgttgg atcggtcagc caccaggata 1740
 gaatgaagtg ctgctggag tggaactgga agatgagtgt gcaggctgta cggatggaac 1800
 cttcagaggc actcggtatt tcacctgtgc cctgaagaag gcgctgtttg tgaactgaa 1860
 gagctgcagg cctgactcta ggtttgcac attgcagccg gtttccaatc agattgagcg 1920
 ctgtaactct ttagcatttg gaggtactt aagtgaagta gtagaagaaa atactccacc 1980
 aaaaatggaa aaagaaggct tggagataat gattgggaag aagaagagca tccagggtca 2040
 ttacaattct tgttacttag actcaacctt attctgctta tttgctttta gttctgttct 2100
 ggacactgtg ttacttagac ccaaaagaaa gaacgatgta gaattattata gtgaaacca 2160
 agagctactg aggacagaaa ttgttaatcc tctgagaata tatggatatg tgtgtgccac 2220
 aaaaattatg aaactgagga aaatacttga aaaggtggag gctgcacag gatttacctc 2280
 tgaagaaaaa gatcctgagg aattcttgaa tttctgttt catcataatt taagggtaga 2340
 acctttgcta aaaaataagat cagcaggtca aaaggtacaa gattgttact tctatcaaat 2400
 ttttatggaa aaaaatgaga aagttggcgt tcccacaatt cagcagttgt tagaatggc 2460
 ttttatcaac agtaacctga aatttgcaga ggaccatca tgtctgatta ttcagatgcc 2520
 tctgatttga aaagacttta aactatttaa aaaaattttt cttctctctg aattaaatat 2580
 aacagattta ctgaaagaca ctcccagaca gtgcgggata tgtggagggc ttgcaatgta 2640
 tgagtgtaga gaatgtacg acgatccgga catctcagct ggaaaaatca agcagttttg 2700
 taaaacctgc aacactcaag tccaccttca tccgaagagg ctgaatcata aatataaacc 2760
 agtgtcactt cccaaagact taccgactg ggactggaga cagggctgca tcccttgcca 2820
 gaatatggag ttatttctgt tctctgcac agaaacaagc cactatgttg cttttgtgaa 2880
 gtatgggaag gacgattctg cctggctctt ctttgacagc atggccgac gggatgggtg 2940
 tcagaatggc ttcaacatc ctcaagtcac cccatgcccc gaagtaggag agtacttga 3000
 gatgtctctg gaagacctgc attccttggg ctccaggaga atccaaggct gtgcacgaag 3060
 actgctttgt gatgcatata tgtgcatgta ccagagtcca acaatgagtt tgtacaaata 3120
 actgggggtca tgggaaagg caaagaaact gaaggcagag tcttaacgtt gcactttatt 3180
 cgagctggca gttctgttca cgtccattgc cggcaatgga tgtctttgtg gtgatgatcc 3240
 ttcagaaaag gatgcctctg tttaaaaaca aattgctttt gtgtccctga agtattta 3300
 aagaagcatt ttgactcta gaaagtatgt ttgtgttggg ttttaagaa gtctaaatga 3360
 agttattaat acctgaagct ttaagttaag tgcattgatc atatgatatt tttggaagca 3420
 tacaatttta attgtggaag tttaaagcct cttttagtcc attgagaatg taaataaatg 3480
 tgtcttcttt atggaccaag gatatgaaat ctttttctt ttgtagctaa cggttgcctt 3540
 gaggaagaaa taatttgggt ttattaaag tctactctca atccagttat tagagatgta 3600
 ctgagtttga tttgttaatc ctttctatat actgctgac ttgcatgtct acaatctgct 3660
 cagtttttct gtgtttctgc aatagtgggt agaaaaatac ttaaatccc ttaatgggtg 3720
 tgttttctat ttgttctggg tttagataaa atgagtgaat ctgtccccc atgtccattt 3780
 ttgaagtgat tttcctggag gattagggta ttttagcatt gaagctctt atccatagta 3840
 gttactgtca gctaacaggt ttttaagc ttttaactat taatatttta tggaaatggg 3900
 caaagtaaat tgatgaaaga attggagtga taatgtcct ttacaacat acagtccata 3960
 agaaaatgaa tttggcatat agaattatta caatttctg ggagagatgg atatttaaac 4020
 ctctattatt ttgacaaga ctgtctagaa cttaagttt atctgtcagc cagtactccc 4080
 attaaattca gtgtagtctt acttgataga atcagatat ttatcgaaat gttagcagca 4140
 gcttcatcct cttctgatt aaagtaagta gaaatggggt gttttgtta ataacagcca 4200


```

tagtgtgtgt ttagaccaca gcggtgtgtg tagaccagga ccatagatga tacatgtcag 4260
tgctgtggaa tgtgcattct ctgagtgttg ttttgggta tcattgtctt tcctgaatga 4320
ctttctaact gtgcagaaag gcagaaaagt catcatatgt atatgtcata tgactttata 4380
aaatatttaa tgtgacaaaa agtggaaaga atctttacaa accctgcaat tactttttta 4440
aaggcacttt tactctttgg ttttatcatt ccattttgct aatatttact agctttataa 4500
attacagtaa ggtacaaaaa aaaaaaa 4527

```

```

<210> 26
<211> 870
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2508327

```

```

<400> 26
ggaggaatga gttaggttcc cgggtgcggg acagtttttt tttctttttt aaaacagaca 60
cagctactga gtgcaatgcc gcctccacag aaaatcccaa gcgtcagacc ctccaagcag 120
aggaaaagct tggcaatcag acaagaggaa gttgctggaa tccgggcaaa gttccccaac 180
aaaatccccg tggtagtgga gcgtaccccc agggagacgt tcctgcccc gctggacaaa 240
accaagttcc tgggtccgca ggagctgacc atgacccagt tcctcagcat catccggagc 300
cgcattggtc tgagagccac ggaagccttt tacttgctgg tgaacaacaa gagcctgggc 360
agcatgagcg caacctggc agagatctac agagactaca aggatgagga tggcttcgtg 420
tacatgacct acgcctccca ggagacattt ggctgcctgg agtcagcagc cccaggggat 480
gggagcagcc ttgaggacag accctgcaat cctctctagc ccatgtcggg aaggatgtgt 540
gctctgacag acgtgtcaga tgctggcaga agggattggt tttctcctgt gtatacagt 600
gaggagtctg agaagcaggg atgcctgggg tgatcagctc caaccagtgg cagcagagt 660
gtggctcttt cctagtttag ttttttttcc cgtttttttg tgtccttcta agaaaaatgt 720
gggcccggcc tgaaaggat ataattatca tttttttttt ttgaaacag ggtcttgtct 780
tactgccttg gttggagcac agtgttgcc tggattgtac ctactgtact tccatcctgt 840
gcttttaatg tgactcgctg tacttgaaga 870

```

```

<210> 27
<211> 729
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2524555

```

```

<400> 27
gtggccactg cgcagaccag acttcgctcg tactcgtgcg cctcgcttcg gtgagcccca 60
gggcccctgc ctccctcctc ctgcccgtcc gcctccgtcc ccgccctttc atcatccgag 120
tcctgtgtaa ggcattccct aaatccgagc ccgagtgggt ctccccggga aggtacttt 180
ggggagctgg ggggatgcga aacaccctag atactggata atgggggtgg gaaatcgatg 240
atttaagaac aaaaccgaaa aactggcggt ttgtcgtgcc gtcggagggg gacattaaaa 300
aatttcttag tgtttgcccg caaagggtatt gtgcgttgcc ttggaggctg agatatgggg 360
gaatagacaa gtcctttgtt ctgaggttca tctccgagc cccgagcctc ctccagcct 420
cggacggctg cgcgggctgc atctgtgcag cctggcgcg gcggggctgt gctatgacat 480
ctttacagtc cttcttgag agacatgtgt gccagggatg ccgaattgcc gggagagcag 540
cttttccctc gcaaccatgt ctgacaaaac cgatatggct gagatcgaga aattcgataa 600

```

gtcgaaactg aagaagacag agacgcaaga gaaaaatcca ctgccttcca aagaaacgat 660
tgaacaggag aagcaagcag gcgaatcgta atgaggcggtg cgccgccaat atgcactgta 720
cattccaca 729

<210> 28

<211> 2062

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2900717

<400> 28

gagtcctctga agccacagat ctcttaagaa cttctctgtct ccaaaccgtg gctgctcgat 60
aaatcagaca gaacagttaa tectcaattt aagcctgac taacccttag aaacagatat 120
agaacaatgg aagtgcacaac aagattgaca tggaaatgatg aaaatcatct gcgcaagctg 180
cttggaatg tttctttgag tcttctctat aagtctagtg ttcattggagg tagcattgaa 240
gatattggtg aaagatgcag ccgtcaggga tgtactataa caatggctta cattgattac 300
aatatgattg tagcctttat gcttggaaat tatattaatt tacgtgaaag ttctacagag 360
cctaatgatt cctatggtt ttcacttcaa aagaaaaatg acaccactga aatagaaact 420
ttactcttaa atacagcacc aaaaattatt gatgagcaac tgggtgtgtcg tttatcgaaa 480
acggatattt tcattatatg tcgagataat aaaattttatc tagataaaat gataacaaga 540
aacttgaaac taagggttta tggccaccgt cagtatttgg aatgtgaagt ttttcgagtt 600
gaaggaatta aggataacct agacgacata aagaggataa ttaaagccag agagcacaga 660
aataggcttc tagcagacat cagagactat aggccttatg cagacttggg ttcagaaatt 720
cgtattcttt tgggtgggtcc agttgggtct ggaaagtcca gtttttcaa ttcagtcag 780
tctatttttc atggccatgt gactggccaa gccgtagtgg ggtctgatac caccagcata 840
accgagcggg ataggatata ttctgttaaa gatggaaaaa atggaaaatc tctgccattt 900
atgttgtgtg acactatggg gctagatggg gcagaaggag caggactgtg catggatgac 960
attccccaca tcttaaaagg ttgtatgcca gacagatata agtttaattc ccgtaaaacca 1020
attacacctg agcattctac ttttatcacc tctccatctc tgaaggacag gattcactgt 1080
gtgggtctatg tcttagacat caactctatt gacaatctct actctaaaaat gttggcaaaa 1140
gtgaagcaag ttcacaaaga agtattaaac tgtggtatag catatgtggc cttgcttact 1200
aaagtggatg attgcagtga ggttcttcaa gacaactttt taaacatgag tagatctatg 1260
actttctcaa gccgggtcat gaatgtccat aaaatgctag gcattcctat ttccaatatt 1320
ttgatggttg gaaattatgc ttcagatttg gaactggacc ccatgaagga tattctcacc 1380
ctctctgcac tgaggcagat gctgcgggct gcagatgatt ttttagaaga ttgacctctt 1440
gaggaaaactg gtgcaattga gagagcgtta cagccctgca tttgagataa gttgccttga 1500
ttctgacatt tggcccagcc tgtactgggtg tgccgcaatg agagtcaatc tctattgaca 1560
gcctgcttca gattttgctt ttgttcgttt tgcccttctgt ccttggaaac gtcatactc 1620
aagttcaaag gccaaaacct gagaagcggg gggctaagat aggtcctact gcaaaccacc 1680
cctccatatt tccgtaccat ttacaattca gtttctgtga catcttttta aaccactgga 1740
ggaaaaatga gatattctct gagatattct ctaattttatt cttctataac actctatata 1800
gagctatgtg agtactaata acattgaata atagttataa aattattgta tagacatctg 1860
cttcttaaac agattgtgag ttctttgaga aacagcgtgg attttactta tctgtgtatt 1920
cacagagctt agcacagtgc ctggtaata gcaagcatac ttgccattac ttttcttcc 1980
cactctctcc aacatcacat tcactttaaa tttttctgta tatagaaagg aaaactagcc 2040
tgggcaacat gatgaaaccc ct 2062

<210> 29

<211> 1020

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3088904

<400> 29

```
ctcgccctgcc accggtgcac ccagtcgcct caccagccc agtcgcgtccg gtcctcaccg 60
cctgccgggcc ggcccacccc ccaccgcagc catggacgcc atcaagaaga agatgcagat 120
gctgaaggag aacgccatcg accgcgccga gcaggccgaa gccgacaaga agcaagctga 180
ggaccgctgc aagcagctgg aggaggagca gcaggccctc cagaagaagc tgaaggggac 240
agaggatgag gtggaaaagt attctgaatc cgtgaaggag gcccaggaga aactggagca 300
ggccgagaag aaggccactg atgctgaggg agatgtggcc tccctgaacc gccgcattca 360
gctgggtgag gaggagctgg accgggcccc ggagcgcctg gctacagccc tgcagaagct 420
ggaggaggcc gagaaggcgg ctgatgagag cgagagagga atgaaggta tcaaaaaccg 480
ggccatgaag gatgaggaga agatggaaact gcaggagatg cagctgaagg aggccaaagca 540
catcgctgag gattcagacc gcaaatatga agaggtggcc aggaagctgg tgatcctgga 600
aggagagctg gacgcctcgg aggagagggc tgaggtggcc gagagccgag ccagacagct 660
ggaggaggaa ctctgaacca tggaccaggc cctcaagtc ctgatggcct cagaggagga 720
gtattccacc aaagaagata aatatgaaga ggagatcaaa ctgttgagg agaaagctgaa 780
ggaggctgag acccgagcag agtttgcga gaggtctgtg gcaaagtgg agaaaaccat 840
cgatgacctt gaagagacct tggccagtc caaggaggag aacgtcgaga ttcaccagac 900
cttgaccag accctgctgg aactcaacaa cctgtgaggg ccagccccc cccagccag 960
gctatggttg ccccccac ccaataaac tgatgttact agcctctcaa aaaaaaaaaa 1020
```

<210> 30

<211> 1120

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3745193

<400> 30

```
cggtgccacc gcggcgacga ggagtctgca atgccgagtg gaggaaggag gaaccggagt 60
gtgagcagta gctgggtggg cagcatggct gggatcacca ccatcgaggc agtgaagcgc 120
aagatccagg ttctgcagca ccaggcagat gatgcagagg agtgagctga gcacctccag 180
tgagaagctg agggaaaaag gtgggcctgg gaacaggcag aggctgaagt ggcctccgtg 240
aacggtagga tccagctggt tgaagaggag ctggactgtg ctgaggagcg cctggccact 300
gccctgcaaa agctggaaga agcgggaaaa gctgctgatg agagtgaag agatacaaa 360
gttattgaaa tctgggcctt aaaagatgaa gaagatggaa ctccaggaaa tccaactcaa 420
agaagctaag cacattgcag atgaggcaga tgggaagtat gaagagggtg ctcgtaagtt 480
ggtgatcatt gaaggagaca tgggatgcac agaggaaacga gctgagctgg cagagtcccg 540
ttgctgagag atggatgagc agatcagact gatggaccag aacctgaagt gtctgagtcg 600
agctgaagaa aagtactctc aaaaagaaga caaatgtgag gaagagatga agattcttac 660
tgataatctc aaggaggcag agaccatgac tgagttggct gagagatcag tagccaagct 720
ggaaaagaca attgatgact tgaagataa actgaaatgc accaaagagg aacacctctg 780
tacacaaagg atgctggacc agactttgct tgacctgaat gagatgtaga atgccccagt 840
cccaccctgc tgctgtcctc tctctgacc ctgactctgc ctgaggccag cctgcccga 900
gctgaccttt acctgagggc tgatctttta cgggaaggct gctttctcct ttgcccacc 960
ctcctctccc tgcctctttt tcaccaaact gtctctgctt ctctctggag attccagctg 1020
ggctagaggc tgagaacctt tgcaaacac atttaagga atgtgagccc aatgcataat 1080
gtcttttaaa atcatgttga gaaaaaaaaa atacataata 1120
```

<210> 31
<211> 1471
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3822123

<400> 31
caggcccagc tgagaggtgc gcgggagagg acagcggcag cgatgcggga atgcatatca 60
gtccacgtgg gccaaagcggg agttcagatt ggcaatgcct gctgggagct cttctgcctg 120
gaacacggca tccaggcaga cggcactttt gatgctcaag ctagcaagat caacgatgat 180
gactccttca ccaccttttt cagcgagact ggcaatggga agcatgtgcc ccgggcccgtc 240
atgatagatc tggagcctac tgtagtggat gagggttcggg caggaacctc ccgccagctc 300
ttccatccag agcagctgat cacaggaaa gaggatgcag ccaacaacta tgcccggggc 360
cactacacgg tgggcaagga gagcattgac ctggtgctgg accgcatacg gaagctgaca 420
gatgcttctc ctggcctgca gggcttctct attttccaca gttttggtgg gggcactggc 480
tcgggcttca cttctctgct gatggaacgc ctctccctgg attatggcaa gaaatccaag 540
ctggaattct ccatctaccc agccccccag gtgtctacag ccgtgggtcga gccctacaac 600
tcttatctga ccacccacac caccctggag cactcagact gtgccttcat ggtggacaac 660
gaagcaatct atgacatctg ccgcccgaac ctagacatcg agcgcaccaac ctacaccaac 720
ctcaatcgcc tcattagcca aattgtctcc tccatcacag cttctctgctg ctttgacggg 780
gccctcaatg tggacctgac agagttccag accaaccctgg tgccctaccc tcgcatccac 840
ttccccctgg ccacatctgc accagtcac tctgcagaaa aggcatacca cgagcagctg 900
tcgggtggcag agatcaccaa tgccctgctt gagcctgcca accagatggt aaagtgtgat 960
ccccggcagc gcaagtacat ggcctgctgc ctgctgtacc gtggagatgt ggtgcccagg 1020
gatgtcaacg ctgccattgc cgccatcaag accaagcgca gcattcagtt tgtggactgg 1080
tgccccacag gcttcaaggt tggatcaac taccagcctc ccactgtggt gcctgggggt 1140
gacctggcca aggtgcagcg tgccgtgtgc atgctgagca acacgaccgc catcgccgag 1200
gcctggggccc gcctggacca caagtccgac ctgatgtatg ccaagagggc gtttgtgcac 1260
tggtatgtgg gtgagggcat ggaggagggt gagggttctcg aggccctgga ggatattggct 1320
gccctggaga aggattatga ggagggtggc atcgactcct atgaggacga ggatgaggga 1380
gaagaataaa gcagctgcct ggagcctatt cactatgttt attgcaaaat ctttccgaaa 1440
taaacagttt ccttgcaaaa aaaaaaaaaa a 1471

<210> 32
<211> 1079
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4217506

<400> 32
cagcccttct cacactcgac ccgcagaaac caccacacct caccatgtct gacgaggaag 60
ttgaacaggt ggaggagcag tacgaagaag aagaggaagc ccatgaggaa gctgcagaag 120
tccatgagga agttcatgaa ccagaggaag ttcaagaaga caccgcagag gaggacgcgg 180
aagaggagaa accgagacce aaactcactg ctccctaagat cccagaaggg gagaaagtgg 240
acttcgatga catccagaag aagcgtcaga acaaaagacct aatggagctc caggccctca 300
tcgacagcca ctttgaagcc cggaagaagg aggaggagga gctggtcgct ctcaaagaga 360
gaatcgagaa gcgccgtgca gagagagcgg agcagcagag gattcgtgca gagaaggaga 420

gggagcgcca gaacagactg gcggaggaaa aggccagaag ggaggaggag gatgccaaga 480
ggagggcaga ggacgacctg aagaagaaga aagctctgtc ttccatggga gccaaactaca 540
gcagctacct ggccaaggct gaccagaaga gaggaagaa gcagacagcc cgggaaatga 600
agaagaagat tctggctgag agacgcaagc cgctcaacat cgatcacctt ggtgaagaca 660
aactgaggga caaggccaag gagctctggg agaccctgca ccagctggag attgacaagt 720
tcgagtttgg ggagaagctg aaacgccaga aatatgacat caccacgctc aggagccgca 780
ttgaccaggc ccagaagcac agcaagaagg ctgggacccc agccaagggc aaagtcggcg 840
ggcgctggaa gtagagaggc cagaaaggcc cctcgaggca gagaccctcc gccctcttgc 900
acaccagggc cgctcgtggg actccacatc ctccagcccc cacaatcctg tcaggggctc 960
cctgacagtc ctgggggtgg agaggccatc ccggggcgtc ccccgctct gtgtccttgc 1020
tgcttctatc ccctggggcc tgtgaataaa gctgcagaac ccccaaaaaa aaaaaaaaa 1079

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :

C12N 15/12, C07K 14/47, C12Q 1/68,
C07K 16/18, A61K 38/17

A3

(11) International Publication Number:

WO 00/17355

(43) International Publication Date:

30 March 2000 (30.03.00)

(21) International Application Number:

PCT/US99/21565

(22) International Filing Date:

17 September 1999 (17.09.99)

(30) Priority Data:

60/172,226

18 September 1998 (18.09.98) US

60/131,321

27 April 1999 (27.04.99) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US

60/172,226 (CIP)

Filed on

18 September 1998 (18.09.98)

US

60/131,321 (CIP)

Filed on

27 April 1999 (27.04.99)

(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LAL, Preeti' [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230

Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US).

(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report:

6 July 2000 (06.07.00)

(54) Title: HUMAN CYTOSKELETON ASSOCIATED PROTEINS

(57) Abstract

The invention provides human cytoskeleton associated proteins (CYSKP) and polynucleotides which identify and encode CYSKP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CYSKP.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C07K14/47 C12Q1/68 C07K16/18 A61K38/17		International Application No. PCT/US 99/21565
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K C12Q A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YASUHIKO KOYANO ET AL.: "Molecular cloning and characterization of CDEP, a novel human protein containing the Ezrin-like domain of the band 4.1 superfamily and the Dbl homology domain of Eho Guanine Nucleotide Exchange Factors." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, no. 2, 18 December 1997 (1997-12-18), pages 369-375, XP002124973 ORLANDO, FL US abstract page 370, right-hand column, paragraph 2 -page 372, left-hand column, paragraph 1; figure 2 page 372, right-hand column, paragraph 2 -page 374, left-hand column, paragraph 1 --- -/--	1-16,19
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family		
Date of the actual completion of the international search 8 December 1999		Date of mailing of the international search report 31.03.00
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016		Authorized officer MONTERO LOPEZ B.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/21565

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 99 28458 A (CHUGAI SEIYAKU KABUSHIKI KAISHA) 10 June 1999 (1999-06-10) figure 1 & AU 12615 99 A</p> <p>-----</p>	1-16,19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/21565

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 19
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 17, 18, 20
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheets

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-20 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:2, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:18, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

2. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:3, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:19, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

3. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:4, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:20, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

4. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:5, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:21, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

5. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:6, variant.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:22, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

6. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:7, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:23, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

7. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:8, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:24, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

8. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:9, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:25, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

9. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:10, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:26, expression vector and host cell comprising the

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

10. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:11, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:27, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

11. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:12, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:28, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

12. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:13, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:29, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

13. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:14, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:30, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

14. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:15, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:31, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

15. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:16, variant thereof, polynucleotides encoding the same and variants thereof, polynucleotide comprising sequence SEQ ID NO:23, expression vector and host cell comprising the polynucleotides; use of the polynucleotides in hybridization tests and for production of the polypeptide; pharmaceutical composition comprising the polypeptide; antibody, agonist and antagonist directed to the polypeptide, and uses thereof in a therapeutic treatment.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17, 18, 20

Present claims 17, 18, 20, directed to agonists and antagonists relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not to be found, however, for any specific example of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for claims 17, 18 and 20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 99/21565

Patent document
cited in search report

Publication
date

Patent family
member(s)

Publication
date

WO 9928458

A

10-06-1999

AU

1261599 A

16-06-1999